Note: Descriptions are shown in the official language in which they were submitted.
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
1
NOVEL MINOR HISTOCOMPATIBILITY ANTIGENS AND USES THEREOF
CROSS-REFERENCE TO RELATED APPLICATIONS
The present application claims the benefit of United States provisional
application serial
No. 62/113,727 filed on February 9, 2015, which is incorporated herein by
reference in its
entirety.
TECHNICAL FIELD
The present invention generally relates to histocompatibility antigens, and
more
specifically to minor histocompatibility antigens (MiHAs) and use thereof, for
example in
immunotherapies.
BACKGROUND ART
While several treatment modalities have proven effective for cancer
immunotherapy,
cancer immunotherapists will undoubtedly need more than one weapon in their
therapeutic
armamentarium. In particular, different approaches are required for tumors
with high vs. low
mutation loads.1 Solid tumors induced by carcinogens (e.g., melanoma, lung
cancer) express
numerous mutations that create tumor-specific antigens (TSAs) which can be
targeted using
two approaches: injection of ex vivo expanded tumor-infiltrating lymphocytes
and administration
of antibodies against checkpoint molecules." However, TSAs are exceedingly
rare on
hematologic cancers (HCs), because of their very low mutation load, and
alternative targets
must therefore be found for immunotherapy of HCs.1 T cells redirected to CD19
or CD20
antigen targets with engineered chimeric antigen receptors are spectacularly
effective for
treatment of B-cell malignancies and represent a breakthrough in cancer
immunotherapy.45
However, whether chimeric antigen receptors might be used for treatment of
myeloid
malignancies remains a matter of speculation.6
Major histocompatibility complex (MHC) molecules are transmembrane
glycoproteins
encoded by closely linked polymorphic loci located on chromosome 6 in humans.
Their primary
role is to bind peptides and present them to T cells. MHC molecules (HLA in
humans) present
thousands of peptides at the surface of human cells. These MHC-associated
peptides (MAPs)
are referred to as the immunopeptidome. The immunopeptidome of identical twins
(AKA
syngeneic individuals) is identical. By contrast, MAPs present on cells from
HLA-identical non-
syngeneic individuals are classified into two categories: i) monomorphic MAPs
which originate
from invariant genomic regions and are therefore present in all individuals
with a given HLA
type, and ii) polymorphic MAPs (AKA MiHAs) which are encoded by polymorphic
genomic
regions and are therefore present in some individuals but absent in other
individuals. MiHAs are
essentially genetic polymorphisms viewed from a T-cell perspective. MiHAs are
typically
encoded by bi-allelic loci and where each allele can be dominant (generates a
MAP) or
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
2
recessive (generates no MAP). Indeed, a non-synonymous single nucleotide
polymorphism (ns-
SNP) in a MAP-coding genomic sequence will either hinder MAP generation
(recessive allele)
or generate a variant MAP (dominant allele).
Another strategy that can be used for cancer immunotherapy is adoptive T-cell
immunotherapy (ATCI). The term "ATCI" refers to transfusing a patient with T
lymphocytes
obtained from: the patient (autologous transfusion), a genetically-identical
twin donor (syngeneic
transfusion), or a non-identical HLA-compatible donor (allogeneic
transfusion). To date, ATCI
has yielded much higher cancer remission and cure rates than vaccines, and the
most widely
used form of cancer ATCI is allogeneic hematopoietic cell transplantation
(AHCT).
The so-called graft-versus-leukemia (GVL) effect induced by allogeneic
hematopoietic
cell transplantation (AHCT) is due mainly to T-cell responses against host
MiHAs: the GVL is
abrogated or significantly reduced if the donor is an identical twin (no MiHA
differences with the
recipient) or if the graft is depleted of T lymphocytes. More than 400,000
individuals treated for
hematological cancers owe their life to the MiHA-dependent GVL effect which
represents the
most striking evidence of the ability of the human immune system to eradicate
neoplasia.
Though the allogeneic GVT effect is being used essentially to treat patients
with hematologic
malignancies, preliminary evidence suggests that it may be also effective for
the treatment of
solid tumors. The considerable potential of MiHA-targeted cancer immunotherapy
has not been
properly exploited in medicine. In current medical practice, MiHA-based
immunotherapy is
limited to "conventional" AHCT, that is, injection of hematopoietic cells from
an allogeneic HLA-
matched donor. Such unselective injection of allogeneic lymphocytes is a very
rudimentary form
of MiHA-targeted therapy. First, it lacks specificity and is therefore highly
toxic: unselected
allogeneic T cells react against a multitude of host MiHAs and thereby induce
graft-versus-host-
disease (GVHD) in 60% of recipients. GVHD is always incapacitating and
frequently lethal.
Second, conventional AHCT induces only an attenuated form of GVT reaction
because donor T
cells are not being primed (pre-activated) against specific MiHAs expressed on
cancer cells
prior to injection into the patient. While primed T cells are resistant to
tolerance induction, naïve
T cells can be tolerized by tumor cells.
It has been demonstrated in mice models of AHCT that, by replacing unselected
donor
lymphocytes with CD8+ T cells primed against a single MiHA, it was possible to
cure leukemia
and melanoma without causing GVHD or any other untoward effect. Success
depends on two
key elements: selection of an immunogenic MiHA expressed on neoplastic cells,
and priming of
donor CD8+ T cells against the target MiHA prior to AHCT. A recent report
discusses why MiHA-
targeted ATCI is so effective and how translation of this approach in the
clinic could have a
tremendous impact on cancer immunotherapy8.
High-avidity T cell responses capable of eradicating tumors can be generated
in an
allogeneic setting. In hematological malignancies, allogeneic HLA-matched
hematopoietic stem
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
3
cell transplantation (ASCT) provides a platform for allogeneic immunotherapy
due to the
induction of T cell-mediated graft-versus-tumor (GVT) immune responses.
Immunotherapy in an
allogeneic setting enables induction of effective T cell responses due to the
fact that T cells of
donor origin are not selected for low reactivity against self-antigens of the
recipient. Therefore,
high-affinity T cells against tumor- or recipient-specific antigens can be
found in the T cell
inoculum administered to the patient during or after ASCT. The main targets of
the tumor-
reactive T cell responses are polymorphic proteins for which donor and
recipient are disparate,
namely MiHAs.
However, implementation of MiHA-targeted immunotherapy in humans has been
limited mainly by the paucity of molecularly defined human MiHAs. Based on the
MiHAs
currently known, only 33% of patients with leukemia would be eligible for MiHA-
based ATCI.
MiHA discovery is a difficult task because it cannot be achieved using
standard genomic and
proteomic methods. Indeed, i) less than 1% of SNPs generate a MiHA and ii)
current mass
spectrometry methods cannot detect MiHAs.
Thus, there is a need for the identification of novel MiHAs that may be used
in
immunotherapies.
The present description refers to a number of documents, the content of which
is
herein incorporated by reference in their entirety.
SUMMARY OF THE INVENTION
The present invention relates to the following items 1 to 53:
1. A Minor Histocompatibility Antigen (MiHA) peptide of 8 to 14 amino
acids of the formula I
Z1-X1-Z2 (I)
wherein
Z1 is an amino terminal modifying group or is absent;
X1 is a sequence comprising at least 8 contiguous residues of one of the
peptide sequences set
forth in Table VI and comprising the polymorphic amino acid depicted; and
Z2 is a carboxy terminal modifying group or is absent;
Table VI
Sequence SEQ ID NO: Sequence SEQ ID NO:
SEESAVPK/ERSW 40-42 AELQ/KGFHRSF 152-
154
SEESAVPE/KRSW 40-42 HLEEQIA/PKV 4-6
QELEEKLNI/ML 85-87 H LEEQ I P/AKV 4-6
REV/ALELDSI 88-90 T/ILLEDGTFKV 155-
157
R/QLAPTLSQL 91-93 IfTLLEDGTFKV 155-
157
QEFID/NNPKW 94-96 VIAEI/VLRGV 158-
160
EEIPV/ISSHY 10-12 AEI/VLRGVRL 263-
265
EEIPV/ISSHYF 13-15 KLAEN I D/EAQL
161-163
AEELG/AGPVHAL 97-99 AEN I D/EAQLKRM
164-166
AE/AIQEKKEI 16-18 FLQAKQIA/TL 167-
169
SESEDRLVA/G 100-102 DEIVCT/I/RQHW 170-
173
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
4
ILSEVERN L/F 103-105 YTVVEEVF/CRV 174-176
EENGRKEIDI/VKKY 106-108 KTDKTLVL/M/VL 177-
180
QEN/DIQ/HNLQL 19-23 SQVQVPLEA/P 181-183
QEN/DIQ/HNLQL 19-23 EEYEELLH/RY 184-186
QEEQTR/KVAL 109-111 EEYEELLR/HY 184-
186
I/SLAPCKLETV 112-114 TEGD/EALDALGLKRY 187-189
S/ILAPCKLETV 112-114 GQ/HYTDLLRL 190-192
RSVDVTNT/ITFL 115-117 EEALGLYH/QW 55-57
VEEADGN/HKQW 24-26 GE/DYFAIKAL 193-195
EEADGN/HKQVVW 27-29 I E/KDRQYKDY 196-
198
AEVEHVVNA/T 118-120 AENDFVH/RRI 199-201
KEIA/TKTVLI 121-123 A/SEIEQKIKEY 7-9
KL/IRGVINQL 124-126 S/AEIEQKIKEY 7-9
KI/LRGVINQL 124-126 SQA/SEIEQKI 58-60
MLRSE/QLLL 127-129 RL/VLQEQHQL 202-204
RQ/EPDLVLRL 130-132 Ft/LLQEELEKL 205-207
LLLAA/TPAQA 133-135 GL/SSPLLQKI 208-210
E/QETAIYKGDY 136-138 TEMEIS/PRAA 61-63
LI/VDTSRHYL 139-141 EQ/RQLLYRSW 211-213
EE/GRGENTSY 30-32 KEINEKSN/SIL 64-66
KILEKEIR/CV 1-3 TEVD/GEAGSQL 214-216
SESKIFt/CVLL 33-35 Q/EEAP ESATVI F 217-219
VEVPEAHQL or absent 142 EE/KEQSQSRW 67-69
NESNTQKTY or absent 36 TETQE/DKNTL 220-
222
MESI/MNPHKY 143-145 AEV/IRAENL 223-225
QELETSI/NKKI 146-148 AELQS/ARLAA 70-72
N/DEVLIHSSQY 149-151 LLWAGPVI/TA 226-228
EEINLQR/INI 37-39 KEN/DQEAEKL 229-231
SLLESSRSQEL/P 79-81 Q/REYQVKLQA 232-234
ALSGHLETV/L 82-84 R/QEYQVKLQA 232-234
EESAVPE/KRSW 43-45 L/M/VEADLPRSW 235-238
EESAVPK/ERSW 43-45 QENQDPR/GRW 73-75
QE/DLIGKKEY 46-48 IEATG/EFDRL 239-241
EELLAVG/SKF 49-51 SL/PDDHVVAV 242-244
EELLAVS/GKF 49-51 QEPFVFH/REF 245-247
GED/GKGIKAL 52-54
'
2. The MiHA peptide of item 1, wherein X1 consists of any one of the
peptide sequences
set forth in Table VI.
3. The MiHA peptide of item 1, wherein X1 is a sequence comprising at least
8 contiguous
residues of one of the peptide sequences set forth in SEQ ID Nos: 1-75 and
comprising the
polymorphic amino acid.
4. The MiHA peptide of item 3, wherein X1 consists of any one of the
peptide sequences
set forth in SEQ ID Nos: 1-75.
5. The MiHA peptide of any one of items 1 to 4, wherein Z1 is absent.
6. The MiHA peptide of any one of items 1 to 5, wherein Z2 is absent.
7. The MiHA peptide of any one of items 1 to 6, wherein said MiHA
peptide consists of any
one of the peptide sequences set forth in Table VI.
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
8. The MiHA peptide of any one of items 1 to 7, wherein said MiHA peptide
consists of any
one of the peptide sequences set forth in SEQ ID Nos: 1-75.
9. The MiHA peptide of item any one of items 1 to 8, wherein said MiHA
derives from a
locus with a minor allele frequency (MAF) of at least 0.1.
5 10. The MiHA peptide of item 9, wherein said MiHA derives from a locus
with a minor allele
frequency (MAF) of at least 0.2.
11. The MiHA peptide of any one of items 1 to 10, wherein said MiHA peptide
binds to a
major histocompatibility complex (MHC) class I molecule of the HLA-A*02:01
allele, and said
peptide sequences are set forth in Table VII:
Table VII:
Sequence SEQ ID NO: Sequence SEQ ID NO:
SLLESSRSQEL/P 79-81 T/ILLEDGTFKV 155-157
ALSGHLETV/L 82-84 IfTLLEDGTFKV 155-157
ILSEVERNL/F 103-105 VIAEI/VLRGV 158-160
I/SLAPCKLETV 112-114 KLAENID/EAQL 161-163
S/ILAPCKLETV 112-114 FLQAKQIA/TL 167-169
RSVDVTNT/ITFL 115-117 YTVVEEVF/CRV 174-176
KL/IRGVINQL 124-126 KTDKTLVL/M/VL 177-180
KI/LRGVINQL 124-126 SQVQVPLEA/P 181-183
MLRSE/QLLL 127-129 GQ/HYTDLLRL 190-192
RQ/EPDLVLRL 130-132 SQA/SEIEQKI 58-60
LLLAA/TPAQA 133-135 RL/VLQEQHQL 202-204
LI/VDTSRHYL 139-141 Ft/LLQEELEKL 205-207
KILEKEIR/CV 1-3 GL/SSPLLQKI 208-210
HLEEQIA/PKV 4-6 LLWAGPVI/TA 226-228
HLEEQIA/PKV 4-6 SL/PDDHVVAV 242-244
'
12. The MiHA peptide of any one of items 1 to 10, wherein said peptide
binds to a major
histocompatibility complex (MHC) class I molecule of the HLA-B*44:03 allele,
and said peptide
sequences are set forth in Table VIII:
Table VIII:
Sequence SEQ ID NO: Sequence SEQ ID NO:
SEESAVPK/ERSW 40-42 EELLAVG/SKF 49-51
SEESAVPE/KRSW 40-42 EELLAVS/GKF 49-51
R/QLAPTLSQL 91-93 GED/GKGIKAL 52-54
QEFID/NNPKW 94-96 AELQ/KGFHRSF 152-154
EEIPV/ISSHY 10-12 AEI/VLRGVRL 263-265
EEIPV/ISSHYF 13-15 AENID/EAQLKRM 164-166
AEELG/AGPVHAL 97-99 DEIVCT/I/RQHW 170-173
AE/AIQEKKEI 16-18 EEYEELLH/RY 184-186
SESEDRLVA/G 100-102 EEYEELLR/HY 184-186
EENGRKEIDI/VKKY 106-108 TEGD/EALDALGLKRY 187-189
QEN/DIQ/HNLQL 19-23 EEALGLYH/QW 55-57
QEN/DIQ/HNLQL 19-23 GE/DYFAIKAL 193-195
QEEQTR/KVAL 109-111 IE/KDRQYKDY 196-198
VEEADGN/HKQW 24-26 AENDFVH/RRI 199-201
EEADGN/HKQVVW 27-29 A/SEIEQKIKEY 7-9
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
6
AEVEHVVNA/T 118-120 S/AEIEQKIKEY 7-9
KEIA/TKTVLI 121-123 TEMEIS/PRAA 61-63
E/QETAIYKGDY 136-138 EQ/RQLLYRSW 211-213
EE/GRGENTSY 30-32 KEINEKSN/SIL 64-66
SESKIFt/CVLL 33-35 TEVD/GEAGSQL 214-216
VEVPEAHQL or absent 142 Q/EEAPESATVIF 217-219
NESNTQKTY or absent 36 EE/KEQSQSRW 67-69
MESI/MNPHKY 143-145 TETQE/DKNTL 220-222
QELETSI/NKKI 146-148 AEV/IRAENL 223-225
N/DEVLIHSSQY 149-151 AELQS/ARLAA 70-72
EEINLQR/INI 37-39 KEN/DQEAEKL 229-231
QELEEKLNI/ML 85-87 Q/REYQVKLQA 232-234
REV/ALELDSI 88-90 R/QEYQVKLQA 232-234
EESAVPE/KRSW 43-45 L/MNEADLPRSW 235-238
EESAVPK/ERSW 43-45 QENQDPR/GRW 73-75
QE/DLIGKKEY 46-48 IEATG/EFDRL 239-241
QEPFVFH/REF 245-247
13. A polypeptide comprising an amino acid sequence of at least one of the
MiHA peptide
defined in any one of items 1 to 12, wherein said polypeptide is of the
following formula la:
Z1-X2-X1-X3-Z2 (la)
wherein
Z1, X1 and Z2 are as defined in any one of items Ito 12; and
X2 and X3 are each independently absent or a sequence of one or more amino
acids,
wherein said polypeptide does not comprise or consist of an amino acid
sequence of a native
protein, and wherein processing of said polypeptide by a cell results in the
loading of the MiHA
peptide in the peptide-binding groove of MHC class I molecules expressed by
said cell
14. A peptide combination comprising (i) at least two of the MiHA peptides
defined in any
one of items 1 to 12; (ii) at least one of the MiHA peptides defined in any
one of items 1 to 12
and at least one additional MiHA peptide.
15. A nucleic acid encoding the MiHA peptide of any one of items 1 to 12 or
the polypeptide
of item 13.
16. The nucleic acid of item 15, which is present in a plasmid or a vector.
17. An isolated major histocompatibility complex (MHC) class I molecule
comprising the
MiHA peptide of any one of items 1 to 12 in its peptide binding groove.
18. The isolated MHC class I molecule of item 17, which is in the form of a
multimer.
19. The isolated MHC class I molecule of item 18, wherein said multimer is
a tetramer.
20. An isolated cell comprising the MiHA peptide of any one of items 1 to
12, the peptide
combination of item 14, or the nucleic acid of item 15 or 16.
21. An isolated cell expressing at its surface major histocompatibility
complex (MHC) class I
molecules comprising the MiHA peptide of any one of items 1 to 12, or the
peptide combination
of item 14, in their peptide binding groove.
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
7
22. The cell of item 21, which is an antigen-presenting cell (APC).
23. The cell of item 22, wherein said APC is a dendritic cell.
24. A T-cell receptor (TCR) that specifically recognizes the isolated MHC
class I molecule of
any one of items 17-19 and/or MHC class I molecules expressed at the surface
of the cell of any
one of items 21-23.
25. One or more nucleic acids encoding the alpha and beta chains of the TCR
of item 24.
26. The one or more nucleic acids of item 25, which are present in a
plasmid or a vector.
27. An isolated CD8+ T lymphocyte expressing at its cell surface the TCR of
item 24.
28. The CD8+ T lymphocyte of item 27, which is transfected or transduced
with the one or
more nucleic acids of item 25 or 26.
29. A cell population comprising at least 0.5% of CD8+ T lymphocytes
according to item 27
or 28.
30. A composition comprising (i) the MiHA peptide of any one of items 1 to
12; (ii) the
polypeptide of item 13; (iii) the peptide combination of item 14; (iv) the
nucleic acid of item 15 or
16; (iv) the MHC class I molecule of any one of items 17-19; (v) the cell of
any one of 20-23; (v)
the TCR of item 24; (vi) the one or more nucleic acids of item 25 or 26; the
CD8+ T lymphocyte
of item 27 or 28; and/or (vii) the cell population of item 29.
31. The composition of item 30, further comprising a buffer, an excipient,
a carrier, a diluent
and/or a medium.
32. The composition of item 30 or 31, wherein said composition is a vaccine
and further
comprises an adjuvant.
33. The composition of any one of items 30 to 32, wherein said
composition comprises the
peptide combination of item 14, or one or more nucleic acids encoding the at
least two MiHA
peptides present in said peptide combination.
34. The composition of any one of items 30 to 33, which comprises the cell
of any one of
items 19-22 and the CD8+ T lymphocyte of item 26 or 27.
35. A method of expanding CD8+ T lymphocytes specifically recognizing one
or more of the
MiHA peptides defined in any one of items 1 to 12, said method comprising
culturing, under
conditions suitable for CD8+ T lymphocyte expansion, CD8+ T lymphocytes from a
candidate
donor that does not express said one or more MiHA peptides in the presence of
cells according
to any one of items 20-22.
36. A method of treating cancer, said method comprising administering to a
subject in need
thereof an effective amount of (i) the CD8+ T lymphocytes of item 27 or 28;
(ii) the cell
population of item 29; and/or (iii) a composition comprising (i) or (ii).
37. The method of item 36, said method further comprising determining one
or more MiHA
variants expressed by said subject in need thereof, wherein the CD8+ T
lymphocytes specifically
recognize said one or more MiHA variants presented by MHC class I molecules.
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
8
38. The method of item 37, wherein said determining comprises sequencing a
nucleic acid
encoding said MiHA.
39. The method of any one of items 36 to 38, wherein said CD8+ T
lymphocytes are ex vivo
expanded CD8+ T lymphocytes prepared according to the method of item 35.
40. The method of any one of items 36 to 39, wherein said method further
comprises
expanding CD8+ T lymphocytes according to the method of item 35.
41. The method of any one of items 36 to 40, wherein said subject in need
thereof is an
allogeneic stem cell transplantation (ASCT) recipient.
42. The method of any one of items 36 to 41, further comprising
administering an effective
amount of the MiHA peptide recognized by said CD8+ T lymphocytes, and/or (ii)
a cell
expressing at its surface MHC class I molecules comprising the MiHA peptide
defined in (i) in
their peptide binding groove.
43. The method of any one of items 36 to 42, wherein said cancer is a
hematologic cancer.
44. The method of item 43, wherein said hematologic cancer is leukemia.
45. An antigen presenting cell or an artificial construct mimicking an
antigen-presenting cell
that presents the MiHA peptide of any one of items 1 to 12 or the peptide
combination of item
14.
46. An in vitro method for producing cytotoxic T lymphocytes (CTLs)
comprising contacting a
T lymphocyte with human class I MHC molecules loaded with the MiHA peptide of
any one of
items 1 to 12 or the peptide combination of item 14 expressed on the surface
of a suitable
antigen presenting cell or an artificial construct mimicking an antigen-
presenting cell for a period
of time sufficient to activate said T lymphocyte in an antigen-specific
manner.
47. An activated cytotoxic T lymphocyte obtained by method of item 46.
48. A method of treating a subject with haematological cancer comprising
administering to
the patient an effective amount of the cytotoxic T lymphocyte of item 47.
49. A method of generating immune response against tumor cells expressing
human class I
MHC molecules loaded with the MiHA peptide of any one of items 1 to 12 or the
peptide
combination of item 14 in a subject, said method comprising administering the
cytotoxic T
lymphocyte of item 47.
50. An antigen presenting cell (APC) artificially loaded with one or more
of the MiHA
peptides defined in any one of items 1 to 12, or the peptide combination of
claim 14.
51. The APC of item 49 for use as a therapeutic vaccine.
52. A method for generating an immune response in a subject comprising
administering to
the subject allogenic T lymphocytes and a composition comprising one or more
of the MiHA
peptides defined in any one of items 1 to 12, or the peptide combination of
claim 14.
53. The method of any one of items 48, 49 and 52 wherein said subject has a
haematological cancer selected from leukemia, lymphoma and myeloma.
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
9
Other objects, advantages and features of the present invention will become
more
apparent upon reading of the following non-restrictive description of specific
embodiments
thereof, given by way of example only with reference to the accompanying
drawings.
BRIEF DESCRIPTION OF DRAWINGS
In the appended drawing:
FIGs. 1A to 1C show the minor allele frequency (MAF) of MiHA-coding loci. FIG.
1A:
Proportion of MiHAs generated by ns-SNPs with high vs. low MAFs. MAFs of ns-
SNPs coding
MiHAs (lighter gray bars) or reported in European-Americans (darker gray bars)
were retrieved
from the Exome Sequencing Project (ESP) (http://evs.gs.washington.edu/EVS/)
and classified
as rare (MAF < 0.05) or frequent (MAF 0.05). As for ns-SNPs in general, most
MiHA-coding
SNPs have a low MAF. FIG. 1B: Number of previously discovered MiHAs24.34
('Reported': lower,
lighter gray portions of the bars) and of new frequent MiHAs identified with
the proteogenomic
approach described herein (upper, darker gray portions of the bars). FIG. 1C:
MAFs of novel
MiHA-coding SNPs in the global population (as reported in dbSNP), in European
Americans
(EA) (according to ESP), or in Europeans (EUR), Admixed Americans (AMR), East
Asians
(EAS), South Asians (SAS) and Africans (AFR) as reported in The 1000 Genomes
Project
(http://www.1000genomes.org; McVean et al., An integrated map of genetic
variation from
1,092 human genomes, Nature 491, 56-65 (01 November 2012)).
FIGs. 2A and 2B show the validation steps and filtering criteria applied to
select and
prioritize the Novel MiHAs. FIG. 2A: Filtering steps used in the
identification of MiHAs. A total of
6,773 sequenced 8-14mer peptides had a HLA-A*02:01 or HLA-B*44:03 predicted
binding
affinity (IC50) below 5,000 nM and encoded by reported ns-SNPs. MiHA that meet
these 2
criteria were further validated. FIG. 2B: Validation steps and criteria
applied to select lead
MiHAs for clinical development.
FIGs. 3A to 3D show the immunogenicity of the newly discovered MiHAs. T
lymphocytes were primed against four newly discovered lead MiHAs: GLRX3-1s,
MIIP-2E,
RASSF1-1s and WDR27-11-. After priming and expansion, T cells were re-exposed
to no
peptide, the MiHA targeted or an irrelevant peptide (HLA-A*02:01 restricted
Epstein-Barr virus
Lmp2426-434 peptide). FIG. 3A: One representative of four IFNy ELISpot
results. FIG. 3B:
Cytokine (IL-2, IFNy) production by T cells primed against WDR27-11-, as
assessed by
intracellular cytokine staining. FIG. 3C: Mean proportion of IFNy-producing
CD8 T cells after a
four-hour re-stimulation in the presence of Brefeldin A (gated on CD8 T
cells). Histograms
represent mean SEM for T cells primed against individual MiHAs (n = 4) or
control peptides *
P < 0.05. FIG. 3D: IFNy production by T cells primed against GLRX3-18 (upper
panels),
RASSF1-1s (middle panels) and MIIP-2E (lower panels), as assessed by
intracellular cytokine
staining.
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
FIGs 4A to 4E show features of MiHAs associated to HLA-A*02:01 and HLA-
B*44:03.
FIG. 4A: All novel MiHA-coding loci are bi-allelic. For most loci, a single
(dominant) allele
generates a MiHA, while the other (recessive) allele does not. In a few cases,
both (co-
dominant) alleles generate MiHAs. Overlapping MiHAs refer to MiHAs that
originate from the
5 same ns-SNP but have different genomic start-end positions. FIG. 4B:
Number of MiHAs
generated per gene. Genes coding 3 or more MiHAs are depicted in a box. FIG.
4C: A
polymorphic density was calculated for all MAP-coding genes by dividing the
number of ns-
SNPs by the length (in nucleotides) of each peptide-coding transcript.
Boxplots (middle band
represents the median) show the distribution of the polymorphic index for MiHA-
coding genes
10 vs. genes coding for non-polymorphic MAPs. Outliers are not shown. The
Wilcoxon rank sum
test was used to compare the two distributions. * P < 0.01. FIG. 4D:
Proportion of MiHAs
derived from a single exon or from two contiguous exons (exon-exon junction).
FIG. 4E: Boxplot
representing the polymorphic density of MiHA-coding exons or exon-exon-
junctions, determined
as in FIG. 4A. Exon-exon junction regions were defined by a range of 78
nucleotides
overlapping two neighboring exons. The Wilcoxon rank sum test was used to
compare the two
distributions. * P < 0.01.
FIG. 5A shows the number of MiHAs selected according to their gene expression
pattern. Expression levels of genes from which derive the previously reported
(n = 7)24,34 and
novel MiHAs (n = 32) with a MAF 0.05, were retrieved from the study of
Fagerberg and
colleagues.3 MiHAs were classified as ubiquitous if expressed in 27 tissues
with > 10 FPKM.3
A ratio of bone marrow (BM) over skin 2 was further considered to select MiHA-
coding
transcripts that are enriched in hematopoietic cells. Left bars: MiHAs
associated to HLA-
A*02:01; middle bars: MiHAs associated to HLA-B*44:03; right bars: total. FIG.
5B: All genes
coding the MiHAs of most clinical interest are expressed in primary acute
myeloid leukemia
(AML) samples. RPKM expression in 128 AML samples was obtained from TCGA.
Boxplots
show the expression distribution of each MiHA gene (expression displayed in
Logic) scale) in
AMLs. The middle line of box plot indicates the median. Because the UTY gene
is on the Y
chromosome, it is expressed only in males. FIG. 5C: Hierarchical clustering
and heatmap
showing mean expression values of MiHA genes in various AML subtypes. Values
were
converted to Log1o(1,000 RPKM +1) for visualization purposes. MiHA gene
expression in AMLs
was obtained from the TCGA and analyzed as in b. AML subtypes correspond to
the French-
American-British classification. Numbers 1-4 on the rightmost side of the
panel identify gene
clusters. Nine MiHA genes that are differentially expressed AML subtypes are
shown in bold
(ANOVA, P < 0.05), and AML subtypes showing a peculiar gene expression pattern
are marked
with dashed outlines (Tukey test, P < 0.05).
FIGs. 6A to 6C show that together the 39 lead MiHAs (of most clinical
interest) (coded
by 24 genes) would enable MiHA-targeted immunotherapy of almost all HLA-
A*02:01;B*44:03
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
11
patients with hematological cancer (HC). FIG. 6A: In a cohort of 13
individuals (10 HLA-
A*02:01-positive and seven HLA-B*44:03-positive) used in the present study, 94
MiHAs coded
by SNPs with a MAF 0.05 were identified. The scipy Python library
(http://www.scipy.org/) was
used to calculate the cumulative number of MiHAs that would be expected to be
discovered by
studying additional individuals. Lower curve: MiHAs associated to HLA-A*02:01;
upper curve:
MiHAs associated to HLA-B*44:03. FIG. 6B: The percentage of donor-recipient
pairs with at
least one therapeutic mismatch increases as a function of the number of MiHAs
considered. A
'therapeutic mismatch' was considered present when a MiHA-coding allele was
found in the
recipient but not in the donor. In the case of Y chromosome-derived MiHAs, a
therapeutic
mismatch was considered in all male-recipient: female-donor pairs. One million
unrelated or
related HLA-A*02:01/B*44:03-positive donor-recipient pairs were randomly
selected from a
virtual population of European-American individuals. MiHA haplotypes of each
donor-recipient
pair were generated based on the allelic frequencies reported in Exome
Sequencing Project for
European Americans. For each pair, the number of MiHA mismatches was
determined for
increasing number of MiHAs considered. Upper curve: unrelated; lower curve:
related. FIG. 6C:
Average number of therapeutic MiHA mismatches found in the randomly selected
donor-
recipient pairs described in FIG. 6B. Left darker gray bars: unrelated; right
lighter gray bars:
related.
DISCLOSURE OF INVENTION
Terms and symbols of genetics, molecular biology, biochemistry and nucleic
acid used
herein follow those of standard treatises and texts in the field, e.g.
Kornberg and Baker, DNA
Replication, Second Edition (W University Science Books, 2005); Lehninger,
Biochemistry, sixth
Edition (W H Freeman & Co (Sd), New York, 2012); Strachan and Read, Human
Molecular
Genetics, Second Edition (Wiley-Liss, New York, 1999); Eckstein, editor,
Oligonucleotides and
Analogs: A Practical Approach (Oxford University Press, New York, 1991); Gait,
editor,
Oligonucleotide Synthesis: A Practical Approach (IRL Press, Oxford, 1984); and
the like. All
terms are to be understood with their typical meanings established in the
relevant art.
The articles "a" and "an" are used herein to refer to one or to more than one
(i.e. to at
least one) of the grammatical object of the article. By way of example, "an
element" means one
element or more than one element. Throughout this specification, unless the
context requires
otherwise, the words "comprise," "comprises" and "comprising" will be
understood to imply the
inclusion of a stated step or element or group of steps or elements but not
the exclusion of any
other step or element or group of steps or elements.
The terms "subject" and "patient" are used interchangeably herein, and refer
to an
animal, preferably a mammal, most preferably a human, who is in the need of
treatment for
cancer using one or more MiHAs as described herein. These term encompass both
adults and
child.
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
12
MiHA peptides and nucleic acids
In an aspect, the present invention provides a polypeptide (e.g., an isolated
or synthetic
polypeptide) comprising an amino acid sequence of a MiHA peptide, wherein said
polypeptide is
of the following formula la:
Z1-X2-X1-X3-Z2 (la)
wherein
Z1, X1 and Z2 are as defined below; and
X2 and X3 are each independently absent or a sequence of one or more amino
acids,
wherein said polypeptide does not comprise or consist of an amino acid
sequence of a native
protein (e.g., the amino acid sequence of the native protein from which the
MiHA peptide is
derived), and wherein processing of said polypeptide by a cell (e.g., an
antigen-presenting cell)
results in the loading of the MiHA peptide of sequence X1 in the peptide-
binding groove of MHC
class I molecules expressed by said cell.
In an embodiment, X2 and/or X3 are each independently a sequence of about 1 to
about 5, 10, 15, 20, 25, 30, 40, 50, 100, 200, 300, 400, 500 or 1000 amino
acids. In an
embodiment, X2 is a sequence of amino acids that is immediately amino-terminal
to the
sequence of XI in the native polypeptide from which the MiHA is derived (see
Table ll for the
Ensembl gene ID corresponding to the gene from which the MiHA described herein
are
derived). In an embodiment, X3 is a sequence of amino acids that is
immediately carboxy-
terminal to the sequence of XI in the native polypeptide from which the MiHA
is derived (see
Table II). For example, MiHA No. 1 derives from the protein Ankyrin repeat
domain 13A
(ANKRD13A), and thus X2 and/or X3 may comprises the one or more amino acids
immediately
amino- and/or carboxy-terminal to the sequence SLLESSRSQEUP (SEQ ID NO: 79) in
ANKRD13A (Ensembl gene ID No. ENSG00000076513, NCB! Reference Sequence:
NP_149112.1). Thus, the sequences immediately amino- and/or carboxy-terminal
to the
sequences of the MiHAs described herein may be easily identified using the
information
available in public databases such as Ensembl, NCB!, UniProt, which may be
retrieved for
example using the SNP ID Nos. and/or Ensembl gene ID Nos. provided in Table II
below. The
entire content and information, including the full sequences of the
transcripts and encoded
polypeptides, corresponding to the SNP ID Nos. and Ensembl gene ID Nos.
provided in Table
II, are incorporated herein by reference.
In another embodiment, X2 and/or X3 are absent. In a further embodiment, X2
and X3
are both absent.
Thus, in another aspect, the present invention provides a MiHA peptide (e.g.,
an
isolated or synthetic peptide) of about 8 to about 14 amino acids of formula I
Z1-X1-Z2 (I)
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
13
wherein Z1 is an amino terminal modifying group or is absent; X1 is a sequence
comprising at
least 8 (preferably contiguous) residues of one of the peptide sequences of
MiHA Nos. 1-93 set
forth in Table I below and comprising the polymorphic amino acid (variation)
depicted
(underlined, e.g., for MiHA No. 1, the C-terminal residue L or P is comprised
in X1 and for MiHA
No. 2, the C-terminal residue V or L is comprised in domain X1, etc.); and Z2
is a carboxy
terminal modifying group or is absent. The reference to MiHA Nos. 1-93
encompasses each of
the variants defined by the sequences depicted. For example, the term "MiHA
No. 1"
(SLLESSRSQEL/13, SEQ ID NO: 79) refers to SLLESSRSQEL (SEQ ID NO: 80) and/or
SLLESSRSQEP (SEQ ID NO: 81).
Table I: Sequences of MiHAs described herein
MIHA MIHA
Sequence SEQ ID NO: Sequence SEQ
ID
No. No. NO:
1 SLLESSRSQEUP 79-81 48 AELQ/KGFHRSF 152-
154
2 ALSGHLETV/L 82-84 49 HLEEQIA/PKV 4-6
3 QELEEKLNI/ML 85-87 50 HLEEQIP/AKV 4-6
4 REV/ALELDSI 88-90 51 T/ILLEDGTFKV 155-
157
5 R/QLAPTLSQL 91-93 52 I/TLLEDGTFKV 155-
157
6 QEFID/NNPKW 94-96 53 VIAEINLRGV 158-
160
7 EEIPV/ISSHY 10-12 54 AEI/VLRGVRL 263-
265
8 EEIPV/ISSHYF 13-15 55 KLAENID/EAQL 161-
163
9 AEELG/AGPVHAL 97-99 56 AENID/EAQLKRM 164-
166
10 AE/AIQEKKEI 16-18 57 FLQAKQIAfTL 167-
169
11 SESEDRLVA/G 100-102 58 DEIVCT/I/RQHW 170-
173
12 ILSEVERNL/F 103-105 59 YTWEEVF/CRV 174-
176
13 EENGRKEIDI/VKKY 106-108 60 KTDKTLVL/M/VL 177-
180
14 QEN/DIQ/HNLQL 19-23 61 SQVQVPLEA/P 181-
183
QEN/DIQ/HNLQL 19-23 62 EEYEELLH/RY 184-186
16 QEEQTR/KVAL 109-111 63 EEYEELLR/HY 184-
186
17 I/SLAPCKLETV 112-114 64 TEGD/EALDALGLKRY 187-
189
18 S/ILAPCKLETV 112-114 65 GQ/HYTDLLRL 190-
192
19 RSVDVTNT/ITFL 115-117 66 EEALGLYH/QW 55-57
VEEADGN/HKQW 24-26 67 GE/DYFAIKAL 193-195
21 EEADGN/HKQWW 27-29 68 IE/KDRQYKDY 196-
198
22 AEVEHVVNAfT 118-120 69 AENDFVH/RRI 199-
201
23 KEIA/TKTVLI 121-123 70 A/SEIEQKIKEY 7-9
24 KUIRGVINQL 124-126 71 S/AEIEQKIKEY 7-9
KI/LRGVINQL 124-126 72 SQA/SEIEQKI 58-60
26 MLRSE/QLLL 127-129 73 RL/VLQEQHQL 202-
204
27 RQ/EPDLVLRL 130-132 74 R/LLQEELEKL 205-
207
28 LLLAA/TPAQA 133-135 75 GUSSPLLQKI 208-
210
29 E/QETAIYKGDY 136-138 76 TEMEIS/PRAA 61-63
LI/VDTSRHYL 139-141 77 EQ/RQLLYRSW 211-213
31 EE/GRGENTSY 30-32 78 KEINEKSN/SIL 64-66
32 KILEKEIR/CV 1-3 79 TEVD/GEAGSQL 214-
216
33 SESKIR/CVLL 33-35 80 Q/EEAPESATVIF 217-
219
34 VEVPEAHQL or absent* 142 81 EE/KEQSQSRW 67-69
NESNTQKTY or 82
36 TETQE/DKNTL 220-
222
absent*
36 MESI/MNPHKY 143-145 83 AEV/IRAENL 223-
225
37 QELETSI/NKKI 146-148 84 AELQS/ARLAA 70-72
38 N/DEVLIHSSQY 149-151 85 LLWAGPVI/TA 226-
228
39 EEINLQR/INI 37-39 86 KEN/DQEAEKL 229-
231
SEESAVPK/ERSW 40-42 87 Q/REYQVKLQA 232-234
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
14
41 SEESAVPE/KRSW 40-42 88 Ft/QEYQVKLQA 232-234
42 EESAVPE/KRSW 43-45 89 L/M/VEADLPRSW 235-238
43 EESAVPK/ERSW 43-45 90 QENQDPFt/GRW 73-75
44 QE/DLIGKKEY 46-48 91 lEATG/EFDRL 239-241
45 EELLAVG/SKF 49-51 92 SUPDDHVVAV 242-244
46 EELLAVS/GKF 49-51 93 QEPFVFH/REF 245-247
47 GED/GKGIKAL 52-54
* The genes from which these MiHAs are derived are located on chromosome Y.
Accordingly,
this MiHa is present in male but absent in female individuals.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of one of the
peptide sequences of MiHAs 7, 8, 10, 14-15, 20-21, 32, 33, 35, 39-47, 49-50,
66, 70-71, 76, 78,
81, 84 and 90 (SEQ ID Nos: 1-75), wherein said sequence comprises the
polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 1
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 2
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 3
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence of at least 8 amino acids of MiHA
No. 4 set forth in
Table I, wherein said sequence comprises the polymorphic amino acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 5
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 6
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 7
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 8
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 9
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
5 as defined above, wherein X1 is a sequence comprising at least 8 amino
acids of MiHA No. 10
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 11
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
10 In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 12
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 13
15 set forth in Table I, wherein said sequence comprises the polymorphic
amino acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 14
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 15
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 16
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as define (No. 119 or 120) set forth in Table I, wherein said sequence
comprises the
polymorphic amino acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 18
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 19
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 20
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
16
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 21
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 22
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 23
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 24
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 25
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 26
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 27
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 28
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 29
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 30
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 31
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 32
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
17
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 33
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 34
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 35
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 36
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 37
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 38
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 39
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 40
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 41
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 42
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 43
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 44
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
18
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 45
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 46
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 47
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 48
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 49
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 50
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 51
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 52
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 53
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 54
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 55
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 56
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
19
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 57
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 58
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 59
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 60
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 61
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 62
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 63
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 64
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 65
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 66
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 67
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 68
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 69
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
5 as defined above, wherein X1 is a sequence comprising at least 8 amino
acids of MiHA No. 70
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 71
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
10 In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 72
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 73
15 set forth in Table I, wherein said sequence comprises the polymorphic
amino acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 74
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
20 as defined above, wherein X1 is a sequence comprising at least 8 amino
acids of MiHA No. 75
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 76
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 77
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 78
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 79
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 80
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
21
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 81
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 82
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 83
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 84
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 85
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 86
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 87
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 88
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 89
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 90
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 91
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 92
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
22
In another aspect, the present invention provides a MiHA peptide of the
formula I or la
as defined above, wherein X1 is a sequence comprising at least 8 amino acids
of MiHA No. 93
set forth in Table I, wherein said sequence comprises the polymorphic amino
acid depicted.
In an embodiment, the MiHA peptide is able to bind to, or to be presented by,
HLA-A2
molecules (HLA-A*02:01 allele). In another aspect, the present invention
provides an HLA-A2-
binding MiHA peptide of 8-14 amino acids of the formula I as defined above,
wherein X1 is a
sequence of at least 8 amino acids of any one of the MiHA Nos. 1, 2, 12, 17-
19, 24-28, 30, 32,
49-53, 55, 57, 59-61, 65, 72-75, 85 and 92 set forth in Table I, wherein said
sequence
comprises the polymorphic amino acid depicted. In an embodiment, the HLA-A2-
binding MiHA
peptide comprises or consists of the sequence of MiHA Nos. 32 and 49-50.
In an embodiment, the MiHA peptide is able to bind to, or to be presented by,
HLA-B44
molecules (HLA-B*44:03 allele). In another aspect, the present invention
provides an HLA-B44-
binding MiHA peptide of 8-14 amino acids of the formula I as defined above,
wherein X1 is a
sequence of at least 8 amino acids of any one of the MiHA Nos. 3-11, 13-16, 20-
23, 29, 31, 33-
48, 54, 56, 58, 62-64, 66-71, 76-84, 86-91 and 93 set forth in Table I,
wherein said sequence
comprises the polymorphic amino acid depicted. In an embodiment, the HLA-B44-
binding MiHA
peptide comprises or consists of the sequence of MiHA Nos. 7, 8, 10, 14-15, 20-
21, 33, 35, 39-
47, 66, 70-71, 76, 78, 81, 84 and 90.
In an embodiment, the MiHA peptide is derived from a gene that does not
exhibit
ubiquitous expression. The expression "does not exhibit ubiquitous expression"
is used herein
to refer to a gene which, according to the data from Fagerberg et al., Mol
Cell Proteomics 2014
13: 397-406, is not expressed with a FPKM > 10 in all 27 tissues disclosed
therein.
In an embodiment, the MiHA peptide derives from a locus with a minor allele
frequency
(MAF) of at least 0.05 as determined according to data from the dbSNP database
(NCB!) and
the National Heart, Lung and Blood Institute (NHLBI) Exome Sequencing Project
(ESP) (as set
forth in Table II). In an embodiment, the MiHA peptide derives from a locus
with a MAF of at
least 0.1 as determined according to data from the dbSNP database (NCB!)
and/or the NHLBI
Exome Sequencing Project (ESP). In an embodiment, the MiHA peptide derives
from a locus
with a MAF of at least 0.1 as determined according to data from the dbSNP
database (NCB!)
and the NHLBI Exome Sequencing Project (ESP). In an embodiment, the MiHA
peptide derives
from a locus with a MAF of at least 0.15 as determined according to data from
the dbSNP
database (NCB!) and/or the NHLBI Exome Sequencing Project (ESP). In an
embodiment, the
MiHA peptide derives from a locus with a MAF of at least 0.15 as determined
according to data
from the dbSNP database (NCB!) and the NHLBI Exome Sequencing Project (ESP).
In an
embodiment, the MiHA peptide derives from a locus with a MAF of at least 0.2
as determined
according to data from the dbSNP database (NCB!) and/or the NHLBI Exome
Sequencing
Project (ESP). In an embodiment, the MiHA peptide derives from a locus with a
MAF of at least
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
23
0.2 as determined according to data from the dbSNP database (NCB!) and the
NHLBI Exome
Sequencing Project (ESP). In an embodiment, the MiHA peptide derives from a
locus with a
MAF of at least 0.25 as determined according to data from the dbSNP database
(NCB!) and/or
the NHLBI Exome Sequencing Project (ESP). In an embodiment, the MiHA peptide
derives from
a locus with a MAF of at least 0.25 as determined according to data from the
dbSNP database
(NCB!) and the NHLBI Exome Sequencing Project (ESP). In an embodiment, the
MiHA peptide
derives from a locus with a MAF of at least 0.3 as determined according to
data from the dbSNP
database (NCB!) and/or the NHLBI Exome Sequencing Project (ESP). In an
embodiment, the
MiHA peptide derives from a locus with a MAF of at least 0.3 as determined
according to data
from the dbSNP database (NCB!) and the NHLBI Exome Sequencing Project (ESP).
In an
embodiment, the MiHA peptide derives from a locus with a MAF of at least 0.35
as determined
according to data from the dbSNP database (NCB!) and/or the NHLBI Exome
Sequencing
Project (ESP). In an embodiment, the MiHA peptide derives from a locus with a
MAF of at least
0.35 as determined according to data from the dbSNP database (NCB!) and the
NHLBI Exome
Sequencing Project (ESP). In an embodiment, the MiHA peptide derives from a
locus with a
MAF of at least 0.4 as determined according to data from the dbSNP database
(NCB!) and/or
the NHLBI Exome Sequencing Project (ESP). In an embodiment, the MiHA peptide
derives from
a locus with a MAF of at least 0.4 as determined according to data from the
dbSNP database
(NCB!) and the NHLBI Exome Sequencing Project (ESP).
In some embodiments, the present invention provides a MiHA peptide comprising
any
combination/subcombination of the features or properties defined herein, for
example, a MiHA
peptide of the formula I as defined above, wherein the peptide (i) binds to
HLA-A2 molecules,
(ii) derives from a gene that does not exhibit ubiquitous expression and (iii)
derives from a locus
with a MAF of at least 0.1 as determined according to data from the dbSNP
database (NCB!)
and/or the NHLBI Exome Sequencing Project (ESP).
In general, peptides presented in the context of HLA class I vary in length
from about 7
to about 15, or preferably 8 to 14 amino acid residues. In some embodiments of
the methods of
the invention, longer peptide comprising the MiHA peptide sequences defined
herein are
artificially loaded into cells such as antigen presenting cells (APCs),
processed by the cells and
the MiHA peptide is presented by MHC class I molecules at the surface of the
APC. In this
method, peptides/polypeptides longer than 15 amino acid residues (i.e. a MiHA
precursor
peptide, such as those defined by formula la above) can be loaded into APCs,
are processed by
proteases in the APC cytosol providing the corresponding MiHA peptide as
defined herein for
presentation. In some embodiments, the precursor peptide/polypeptide (e.g.,
polypeptide of
formula la defined above) that is used to generate the MiHA peptide defined
herein is for
example 100, 500, 400, 300, 200, 150, 100, 75, 50, 45, 40, 35, 30, 25, 20 or
15 amino acids or
less. Thus, all the methods and processes using the MiHA peptides described
herein includes
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
24
the use of longer peptides or polypeptides (including the native protein),
i.e. MiHA precursor
peptides/polypeptides, to induce the presentation of the "final" 8-14 MiHA
peptide following
processing by the cell (APCs).
In some embodiments, the above-mentioned MiHA peptide is about 8 to 12 amino
acids long (e.g., 8, 9, 10, 11 or 12 amino acids long), small enough for a
direct fit in an HLA
class I molecule (HLA-A2 or HLA-B44 molecule), but it may also be larger,
between 12 to about
20, 25, 30, 35, 40, 45 or 50 amino acids, and a MiHA peptide corresponding to
the domain
defined by X1 above be presented by HLA molecules only after cellular uptake
and intracellular
processing by the proteasome and/or other proteases and transport before
presentation in the
groove of an HLA class I molecule (HLA-A2 or HLA-B44 molecule), as explained
above.
In an embodiment, the MiHA peptide consists of an amino acid sequence of 8 to
14
amino acids, e.g., 8, 9, 10, 11, 12, 13, or 14 amino acids, wherein the
sequence is the
sequences of any one of MiHA Nos. 1-93 set forth in Table I. In another
aspect, the present
invention provides a MiHA peptide consisting of an amino acid sequence of 8 to
14 amino acids,
e.g., 8, 9, 10, 11, 12, 13, 14 or 15 amino acids, said amino acid sequence
consisting of the
sequence of MIHA Nos. 1-93, preferably MiHAs 7, 8, 10, 14-15, 20-21, 32, 33,
35, 39-47, 49-50,
66, 70-71, 76, 78, 81, 84 and 90 of Table l). In an embodiment, the at least 7
or 8 amino acids
of one of MIHA Nos. 1-93, preferably MiHAs 7, 8, 10, 14-15, 20-21, 32, 33, 35,
39-47, 49-50,
66, 70-71, 76, 78, 81, 84 and 90 of Table I are contiguous amino acids. In an
embodiment, X1 is
a domain comprising at least 8 amino acids of any one of MiHA Nos. 1-93,
preferably MiHAs 7,
8, 10, 14-15, 20-21, 32, 33, 35, 39-47, 49-50, 66, 70-71, 76, 78, 81, 84 and
90, wherein said
sequence comprises the polymorphic amino acid depicted. In another embodiment,
X*1 is a
sequence comprising, or consisting of, the amino acids of any one of MiHA Nos.
1-93,
preferably MiHAs 7, 8, 10, 14-15, 20-21, 32, 33, 35, 39-47, 49-50, 66, 70-71,
76, 78, 81, 84 and
90.
The term "amino acid" as used herein includes both L- and D-isomers of the
naturally
occurring amino acids as well as other amino acids (e.g., naturally-occurring
amino acids, non-
naturally-occurring amino acids, amino acids which are not encoded by nucleic
acid sequences,
etc.) used in peptide chemistry to prepare synthetic analogs of MiHA peptides.
Examples of
naturally occurring amino acids are glycine, alanine, valine, leucine,
isoleucine, serine,
threonine, etc.
Other amino acids include for example non-genetically encoded forms of amino
acids,
as well as a conservative substitution of an L-amino acid. Naturally-occurring
non-genetically
encoded amino acids include, for example, beta-alanine, 3-amino-propionic
acid, 2,3-
diaminopropionic acid, alpha-aminoisobutyric acid (Aib), 4-amino-butyric acid,
N-methylglycine
(sarcosine), hydroxyproline, ornithine (e.g., L-ornithine), citrulline, t-
butylalanine, t-butylglycine,
N-methylisoleucine, phenylglycine, cyclohexylalanine, norleucine (Nle),
norvaline, 2-
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
napthylalanine, pyridylalanine, 3-benzothienyl alanine, 4-chlorophenylalanine,
2-
fluorophenylalanine, 3-fluorophenylalanine, 4-fluorophenylalanine,
penicillamine, 1 ,2,3,4-
tetrahydro-isoquinoline-3-carboxylix acid, beta-2-thienylalanine, methionine
sulfoxide, L-
homoarginine (Hoarg), N-acetyl lysine, 2-amino butyric acid, 2-amino butyric
acid, 2,4,-
5 diaminobutyric acid (D- or L-), p-aminophenylalanine, N-methylvaline,
homocysteine,
homoserine (HoSer), cysteic acid, epsilon-amino hexanoic acid, delta-amino
valeric acid, or 2,3-
diaminobutyric acid (D- or L-), etc. These amino acids are well known in the
art of
biochemistry/peptide chemistry. In an embodiment, the MiHA peptide comprises
only naturally-
occurring amino acids.
10 In embodiments, the MiHA peptides of the present invention include
peptides with
altered sequences containing substitutions of functionally equivalent amino
acid residues,
relative to the above-mentioned sequences. For example, one or more amino acid
residues
within the sequence can be substituted by another amino acid of a similar
polarity (having
similar physico-chemical properties) which acts as a functional equivalent,
resulting in a silent
15 alteration. Substitution for an amino acid within the sequence may be
selected from other
members of the class to which the amino acid belongs. For example, positively
charged (basic)
amino acids include arginine, lysine and histidine (as well as homoarginine
and ornithine).
Nonpolar (hydrophobic) amino acids include leucine, isoleucine, alanine,
phenylalanine, valine,
proline, tryptophan and methionine. Uncharged polar amino acids include
serine, threonine,
20 cysteine, tyrosine, asparagine and glutamine. Negatively charged
(acidic) amino acids include
glutamic acid and aspartic acid. The amino acid glycine may be included in
either the nonpolar
amino acid family or the uncharged (neutral) polar amino acid family.
Substitutions made within
a family of amino acids are generally understood to be conservative
substitutions.
The above-mentioned MiHA peptide may comprise all L-amino acids, all D-amino
acids
25 or a mixture of L- and D-amino acids. In an embodiment, the above-
mentioned MiHA peptide
comprises all L-amino acids.
The MiHA peptide may also be N- and/or C-terminally capped or modified to
prevent
degradation, increase stability or uptake. In an embodiment, the amino
terminal residue (Le., the
free amino group at the N-terminal end) of the MiHA peptide is modified (e.g.,
for protection
against degradation), for example by covalent attachment of a moiety/chemical
group (Z1). Z1
may be a straight chained or branched alkyl group of one to eight carbons, or
an acyl group (R-
CO-), wherein R is a hydrophobic moiety (e.g., acetyl, propionyl, butanyl, iso-
propionyl, or iso-
butanyl), or an aroyl group (Ar-00-), wherein Ar is an aryl group. In an
embodiment, the acyl
group is a C1-C16 or C3-C16 acyl group (linear or branched, saturated or
unsaturated), in a further
embodiment, a saturated C1-C6 acyl group (linear or branched) or an
unsaturated C3-C6 acyl
group (linear or branched), for example an acetyl group (CH3-00-, Ac). In an
embodiment, Z1 is
absent.
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
26
The carboxy terminal residue (i.e., the free carbon/ group at the C-terminal
end of the
MiHA peptide) of the MiHA peptide may be modified (e.g., for protection
against degradation),
for example by amidation (replacement of the OH group by a NH2 group), thus in
such a case Z2
is a NH2 group. In an embodiment, Z2 may be an hydroxamate group, a nitrile
group, an amide
(primary, secondary or tertiary) group, an aliphatic amine of one to ten
carbons such as methyl
amine, iso-butylamine, iso-valerylamine or cyclohexylamine, an aromatic or
arylalkyl amine such
as aniline, napthylamine, benzylamine, cinnamylamine, or phenylethylamine, an
alcohol or
CH2OH. In an embodiment, Z2 is absent.
In an embodiment, the MiHA peptide comprises one of sequences Nos. 1-93,
preferably MiHAs 7, 8, 10, 14-15, 20-21, 32, 33, 35, 39-47, 49-50, 66, 70-71,
76, 78, 81, 84 and
90 set forth in Table I. In an embodiment, the MiHA peptide consists of one of
sequences No. 1-
93, preferably MiHAs 7, 8, 10, 14-15, 20-21, 32, 33, 35, 39-47, 49-50, 66, 70-
71, 76, 78, 81, 84
and 90 set forth in Table I, i.e. wherein Z1 and Z2 are absent.
The MiHA peptides of the invention may be produced by expression in a host
cell
comprising a nucleic acid encoding the MiHA peptides (recombinant expression)
or by chemical
synthesis (e.g., solid-phase peptide synthesis). Peptides can be readily
synthesized by manual
and/or automated solid phase procedures well known in the art. Suitable
syntheses can be
performed for example by utilizing "T-boc" or "Fmoc" procedures. Techniques
and procedures
for solid phase synthesis are described in for example Solid Phase Peptide
Synthesis: A
Practical Approach, by E. Atherton and R. C. Sheppard, published by IRL,
Oxford University
Press, 1989. Alternatively, the MiHA peptides may be prepared by way of
segment
condensation, as described, for example, in Liu et al., Tetrahedron Left. 37:
933-936, 1996;
Baca et al., J. Am. Chem. Soc. 117: 1881-1887, 1995; Tam et al., mt. J.
Peptide Protein Res.
45: 209-216, 1995; Schnolzer and Kent, Science 256: 221-225, 1992; Liu and
Tam, J. Am.
Chem. Soc. 116: 4149-4153, 1994; Liu and Tam, Proc. Natl. Acad. Sci. USA 91:
6584-6588,
1994; and Yamashiro and Li, mt. J. Peptide Protein Res. 31: 322-334, 1988).
Other methods
useful for synthesizing the MiHA peptides are described in Nakagawa et al., J.
Am. Chem. Soc.
107: 7087-7092, 1985. In an embodiment, the MiHA peptide of the formula I or
la is chemically
synthesized (synthetic peptide).
Accordingly, in another aspect, the invention further provides a nucleic acid
(isolated)
encoding the above-mentioned MiHA peptides or a MiHA precursor-peptide. In an
embodiment,
the nucleic acid comprises from about 21 nucleotides to about 45 nucleotides,
from about 24 to
about 45 nucleotides, for example 24, 27, 30, 33, 36, 39, 42 or 45
nucleotides.
"Isolated", as used herein, refers to a peptide or nucleic molecule separated
from other
components that are present in the natural environment of the molecule or a
naturally occurring
source macromolecule (e.g., including other nucleic acids, proteins, lipids,
sugars, etc.).
"Synthetic", as used herein, refers to a peptide or nucleic molecule that is
not isolated from its
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
27
natural sources, e.g., which is produced through recombinant technology or
using chemical
synthesis.
In an embodiment, the above-mentioned MiHA peptide is substantially pure. A
compound is "substantially pure" when it is separated from the components that
naturally
accompany it. Typically, a compound is substantially pure when it is at least
60%, more
generally 75%, 80% or 85%, preferably over 90% and more preferably over 95%,
by weight, of
the total material in a sample. Thus, for example, a polypeptide that is
chemically synthesized or
produced by recombinant technology will generally be substantially free from
its naturally
associated components, e.g. components of its source macromolecule. A nucleic
acid molecule
is substantially pure when it is not immediately contiguous with (i.e.,
covalently linked to) the
coding sequences with which it is normally contiguous in the naturally
occurring genome of the
organism from which the nucleic acid is derived. A substantially pure compound
can be
obtained, for example, by extraction from a natural source; by expression of a
recombinant
nucleic acid molecule encoding a peptide compound; or by chemical synthesis.
Purity can be
measured using any appropriate method such as column chromatography, gel
electrophoresis,
HPLC, etc.
A nucleic acid of the invention may be used for recombinant expression of the
MiHA
peptide of the invention, and may be included in a vector or plasmid, such as
a cloning vector or
an expression vector, which may be transfected into a host cell. In an
embodiment, the
invention provides a cloning or expression vector or plasmid comprising a
nucleic acid
sequence encoding the MiHA peptide of the invention. Alternatively, a nucleic
acid encoding a
MiHA peptide of the invention may be incorporated into the genome of the host
cell. In either
case, the host cell expresses the MiHA peptide or protein encoded by the
nucleic acid.
The vector or plasmid contains the necessary elements for the transcription
and
translation of the inserted coding sequence, and may contain other components
such as
resistance genes, cloning sites, etc. Methods that are well known to those
skilled in the art may
be used to construct expression vectors containing sequences encoding peptides
or
polypeptides and appropriate transcriptional and translational
control/regulatory elements
operably linked thereto. These methods include in vitro recombinant DNA
techniques, synthetic
techniques, and in vivo genetic recombination. Such techniques are described
in Sambrook. et
al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press,
Plainview, N.Y.,
and Ausubel, F. M. et aL (1989) Current Protocols in Molecular Biology, John
Wiley & Sons,
New York, N.Y.
"Operably linked" refers to a juxtaposition of components, particularly
nucleotide
sequences, such that the normal function of the components can be performed.
Thus, a coding
sequence that is operably linked to regulatory sequences refers to a
configuration of nucleotide
sequences wherein the coding sequences can be expressed under the regulatory
control, that
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
28
is, transcriptional and/or translational control, of the regulatory sequences.
"Regulatory/control
region" or "regulatory/control sequence", as used herein, refers to the non-
coding nucleotide
sequences that are involved in the regulation of the expression of a coding
nucleic acid. Thus
the term regulatory region includes promoter sequences, regulatory protein
binding sites,
upstream activator sequences, and the like.
In an embodiment, the MiHA peptide is in solution. In another embodiment, the
MiHA
peptide is in solid form, e.g., lyophilized.
In another aspect, the present invention provides a MHC class I molecule
comprising
(i.e. presenting or bound to) a MiHA peptide. In an embodiment, the MHC class
I molecule is a
HLA-A2 molecule, in a further embodiment a HLA-A*02:01 molecule. In another
embodiment,
the MHC class I molecule is a HLA-B44 molecule, in a further embodiment a HLA-
B*44:03
molecule. In an embodiment, the MiHA peptide is non-covalently bound to the
MHC class I
molecule (i.e., the MiHA peptide is loaded into, or non-covalently bound to
the peptide binding
groove/pocket of the MHC class I molecule). In another embodiment, the MiHA
peptide is
covalently attached/bound to the MHC class I molecule (alpha chain). In such a
construct, the
MiHA peptide and the MHC class I molecule (alpha chain) are produced as a
synthetic fusion
protein, typically with a short (e.g., 5 to 20 residues, preferably about 8-
12, e.g., 10) flexible
linker or spacer (e.g., a polyglycine linker). In another aspect, the
invention provides a nucleic
acid encoding a fusion protein comprising a MiHA peptide defined above fused
to a MHC class I
molecule (alpha chain). In an embodiment, the MHC class I molecule (alpha
chain) ¨ peptide
complex is multimerized. Accordingly, in another aspect, the present invention
provides a
multimer of MHC class I molecule loaded (covalently or not) with the above-
mentioned MiHA
peptide. Such multimers may be attached to a tag, for example a fluorescent
tag, which allows
the detection of the multimers. A great number of strategies have been
developed for the
production of MHC multimers, including MHC dimers, tetramers, pentamers,
octamers, etc.
(reviewed in Bakker and Schumacher, Current Opinion in Immunology 2005, 17:428-
433). MHC
multimers are useful, for example, for the detection and purification of
antigen-specific T cells.
Thus, in another aspect, the present invention provides a method for detecting
or purifying
(isolating, enriching) CD8+ T lymphocytes specific for a MiHA peptide defined
above, the
method comprising contacting a cell population with a multimer of MHC class I
molecule loaded
(covalently or not) with the MiHA peptide; and detecting or isolating the CD8+
T lymphocytes
bound by the MHC class I multimers. CD8+ T lymphocytes bound by the MHC class
I multimers
may be isolated using known methods, for example fluorescence activated cell
sorting (FACS)
or magnetic activated cell sorting (MACS).
In yet another aspect, the present invention provides a cell (e.g., a host
cell), in an
embodiment an isolated cell, comprising the above-mentioned nucleic acid,
vector or plasmid of
the invention, i.e. a nucleic acid or vector encoding one or more MiHA
peptides.
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
29
In another aspect, the present invention provides a cell expressing at its
surface a
MHC class I molecule (e.g., a HLA-A2 or HLA-B44 allele molecule) bound to or
presenting a
MiHA peptide according to the invention. In one embodiment, the host cell is a
primary cell, a
cell line or an immortalized cell. In another embodiment, the cell is an
antigen-presenting cell
(APC).
Nucleic acids and vectors can be introduced into cells via conventional
transformation
or transfection techniques. The terms "transformation" and "transfection"
refer to techniques for
introducing foreign nucleic acid into a host cell, including calcium phosphate
or calcium chloride
co-precipitation, DEAE-dextran-mediated transfection, lipofection,
electroporation, microinjection
and viral-mediated transfection. Suitable methods for transforming or
transfecting host cells can
for example be found in Sambrook et al. (supra), and other laboratory manuals.
Methods for
introducing nucleic acids into mammalian cells in vivo are also known, and may
be used to
deliver the vector DNA of the invention to a subject for gene therapy.
Cells such as APCs can be loaded with one or more MiHA peptides using a
variety of
methods known in the art. As used herein "loading a cell" with a MiHA peptide
means that RNA
or DNA encoding the MiHA peptide, or the MiHA peptide, is transfected into the
cells or
alternatively that the APC is transformed with a nucleic acid encoding the
MiHA peptide. The
cell can also be loaded by contacting the cell with exogenous MiHA peptides
that can bind
directly to MHC class I molecule present at the cell surface (e.g., peptide-
pulsed cells). The
MiHA peptides may also be fused to a domain or motif that facilitates its
presentation by MHC
class I molecules, for example to an endoplasmic reticulum (ER) retrieval
signal, a C-terminal
Lys-Asp-Glu-Leu sequence (see Wang etal., Eur J Immunol. 2004 Dec;34(12):3582-
94).
Compositions
In another aspect, the present invention provides a composition or peptide
combination
comprising any one of, or any combination of, the MiHA peptides defined above
(or a nucleic
acid encoding said peptide(s)). In an embodiment, the composition comprises
any combination
of the MiHA peptides defined above (e.g., any combination of MiHAs Nos. 1-93,
preferably
MiHAs 7, 8, 10, 14-15, 20-21, 32, 33, 35, 39-47, 49-50, 66, 70-71, 76, 78, 81,
84 and 90 set
forth in Table l), or a combination of nucleic acids encoding said MiHA
peptides). For example,
the composition may comprise a first MiHA peptide which correspond to MiHA No.
1 and a
second MiHA peptide that corresponds to MiHA No. 24. Compositions comprising
any
combination/sub-combination of the MiHA peptides defined above are encompassed
by the
present invention. In another embodiment, the combination may comprise one or
more known
MiHAs, such as the known MiHAs disclosed herein (see, e.g., Tables III and V).
In an
embodiment, the composition or peptide combination comprises at least 2, 3, 4,
5, 6, 7, 8, 9, or
10 MiHA peptides, wherein at least one of said MiHA peptide comprising the
MiHAs Nos. 1-93
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
In a further embodiment, a MHC class I molecule (HLA-A2 or HLA-B44) that
presents a
MiHA peptide is expressed at the surface of a cell, e.g., an APC. In an
embodiment, the
invention provides an APC loaded with one or more MiHA peptides bound to MHC
class I
molecules. In yet a further embodiment, the invention provides an isolated MHC
class 1/MiHA
5 peptide complex.
Thus, in another aspect, the present invention provides a composition
comprising any
one of, or any combination of, the MiHA peptides defined above and a cell
expressing a MHC
class I molecule (HLA-A2 or HLA-B44). APC for use in the present invention are
not limited to a
particular type of cell and include professional APCs such as dendritic cells
(DCs), Langerhans
10 cells, macrophages and B cells, which are known to present proteinaceous
antigens on their
cell surface so as to be recognized by CD8+ T lymphocytes. For example, an APC
can be
obtained by inducing DCs from peripheral blood monocytes and then contacting
(stimulating)
the MiHA peptides, either in vitro, ex vivo or in vivo. APC can also be
activated to present a
MiHA peptide in vivo where one or more of the MiHA peptides of the invention
are administered
15 to a subject and APCs that present a MiHA peptide are induced in the
body of the subject. The
phrase "inducing an APC" or "stimulating an APC" includes contacting or
loading a cell with one
or more MiHA peptides, or nucleic acids encoding the MiHA peptides such that
the MiHA
peptides are presented at its surface by MHC class I molecules (e.g., HLA-A2
or HLA-B44). As
noted above, according to the present invention, the MiHA peptides may be
loaded indirectly for
20 example using longer peptides/polypeptides comprising the sequence of
the MiHAs (including
the native protein), which is then processed (e.g., by proteases) inside the
APCs to generate
the MiHA peptide/MHC class I complexes at the surface of the cells.
After loading APCs with MiHA peptides and allowing the APCs to present the
MiHA
peptides, the APCs can be administered to a subject as a vaccine. For example,
the ex vivo
25 administration can include the steps of:
(a) collecting APCs from a first subject, (b) contacting/loading the APCs of
step (a) with a MiHA
peptide to form MHC class 1/MiHA peptide complexes at the surface of the APCs;
and (c)
administering the peptide-loaded APCs to a second subject in need for
treatment.
The first subject and the second subject can be the same individual (e.g.,
autologous
30 vaccine), or may be different individuals (e.g., allogeneic vaccine).
Alternatively, according to
the present invention, use of a MiHA peptide of the present invention for
manufacturing a
pharmaceutical composition for inducing antigen-presenting cells is provided.
In addition, the
present invention provides a method or process for manufacturing a
pharmaceutical
composition for inducing antigen-presenting cells, wherein the method or the
process includes
the step of admixing or formulating the MiHA peptide with a pharmaceutically
acceptable carrier.
Cells such as APCs expressing a MHC class I molecule (HLA-A2 or HLA-B44)
loaded
with any one of, or any combination of, the MiHA peptides defined above, may
be used for
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
31
stimulating/amplifying CD8+ T lymphocytes, for example autologous CD8+ T
lymphocytes.
Accordingly, in another aspect, the present invention provides a composition
comprising any
one of, or any combination of, the MiHA peptides defined above (or a nucleic
acid or vector
encoding same); a cell expressing a MHC class I molecule (HLA-A2 or HLA-B44)
and a T
lymphocyte, more specifically a CD8+ T lymphocyte (e.g., a population of cells
comprising CD8+
T lymphocytes).
In an embodiment, the composition further comprises a buffer, an excipient, a
carrier, a
diluent and/or a medium (e.g., a culture medium). In a further embodiment, the
buffer, excipient,
carrier, diluent and/or medium is/are pharmaceutically acceptable buffer(s),
excipient(s),
carrier(s), diluent(s) and/or medium (media). As used herein "pharmaceutically
acceptable
buffer, excipient, carrier, diluent and/or medium" includes any and all
solvents, buffers, binders,
lubricants, fillers, thickening agents, disintegrants, plasticizers, coatings,
barrier layer
formulations, lubricants, stabilizing agent, release-delaying agents,
dispersion media, coatings,
antibacterial and antifungal agents, isotonic agents, and the like that are
physiologically
compatible, do not interfere with effectiveness of the biological activity of
the active ingredient(s)
and that are not toxic to the subject. The use of such media and agents for
pharmaceutically
active substances is well known in the art (Rowe et al., Handbook of
pharmaceutical excipients,
2003, 4th edition, Pharmaceutical Press, London UK). Except insofar as any
conventional media
or agent is incompatible with the active compound (peptides, cells), use
thereof in the
compositions of the invention is contemplated. In an embodiment, the buffer,
excipient, carrier
and/or medium is a non-naturally occurring buffer, excipient, carrier and/or
medium.
In one embodiment, the MiHA peptides of the invention are used as a vaccine.
In another aspect, the present invention provides an immunogenic composition
comprising one of more of the any one of, or any combination of, the MiHA
peptides defined
above (or a nucleic acid encoding said peptide(s)), and a buffer, an
excipient, a carrier, a diluent
and/or a medium.
For compositions comprising cells (e.g., T lymphocytes), the composition
comprises a
suitable medium that allows the maintenance of viable cells. Representative
examples of such
media include saline solution, Earl's Balanced Salt Solution (Life
Technologies ) or
PlasmaLyte (Baxter International ).
In an embodiment, the composition is an "immunogenic composition" or
"vaccine". The
term "Immunogenic composition" or "vaccine" as used herein refers to a
composition or
formulation comprising one or more MiHA peptides or vaccine vector and which
is capable of
inducing an immune response against the one or more MiHA peptides present
therein when
administered to a subject. Vaccination methods for inducing an immune response
in a mammal
comprise use of a vaccine or vaccine vector to be administered by any
conventional route
known in the vaccine field, e.g., via a mucosa! (e.g., ocular, intranasal,
pulmonary, oral, gastric,
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
32
intestinal, rectal, vaginal, or urinary tract) surface, via a parenteral
(e.g., subcutaneous,
intradermal, intramuscular, intravenous, or intraperitoneal) route, or topical
administration (e.g.,
via a transdermal delivery system such as a patch).
In an embodiment, the MiHA peptide is conjugated to a carrier protein
(conjugate
vaccine) to increase the immunogenicity of the MiHA peptide. The present
invention thus
provides a composition (conjugate) comprising a MiHA peptide and a carrier
protein. For
example, the MiHA peptide may be conjugated to a Toll-like receptor (TLR)
ligand (see, e.g.,
Zom et al., Adv lmmunol. 2012;114:177-201) or polymers/dendrimers (see, e.g.,
Liu et al.,
Biomacromolecules. 2013 Aug 12;14(8):2798-806).
In an embodiment, the immunogenic composition or vaccine further comprises an
adjuvant. "Adjuvant" refers to a substance which, when added to an immunogenic
agent such
as an antigen (MiHA peptides and/or cells according to the present invention),
nonspecifically
enhances or potentiates an immune response to the agent in the host upon
exposure to the
mixture. Examples of adjuvants currently used in the field of vaccines include
(1) mineral salts
(aluminum salts such as aluminum phosphate and aluminum hydroxide, calcium
phosphate
gels), squalene, (2) oil-based adjuvants such as oil emulsions and surfactant
based
formulations, e.g., MF59 (microfluidised detergent stabilised oil-in-water
emulsion), QS21
(purified saponin), AS02 [SBAS2] (oil-in-water emulsion + MPL + QS-21), (3)
particulate
adjuvants, e.g., virosomes (unilamellar liposomal vehicles incorporating
influenza
haemagglutinin), AS04 ([SIBAS4] aluminum salt with MPL), ISCOMS (structured
complex of
saponins and lipids), polylactide co-glycolide (PLC), (4) microbial
derivatives (natural and
synthetic), e.g., monophosphoryl lipid A (MPL), Detox (MPL + M. Phlei cell
wall skeleton), AGP
[RC-529] (synthetic acylated monosaccharide), DC_Chol (lipoidal
immunostimulators able to
self-organize into liposomes), 0M-174 (lipid A derivative), CpG motifs
(synthetic
oligonucleotides containing immunostimulatory CpG motifs), modified LT and CT
(genetically
modified bacterial toxins to provide non-toxic adjuvant effects), (5)
endogenous human
immunomodulators, e.g., hGM-CSF or hIL-12 (cytokines that can be administered
either as
protein or plasmid encoded), Immudaptin (C3d tandem array) and/or (6) inert
vehicles, such as
gold particles, and the like.
In an embodiment, the MiHA peptide(s) or composition comprising same is in
lyophilized form. In another embodiment, the MiHA peptide(s) is/are in a
liquid composition. In a
further embodiment, the MiHA peptide(s) is/are at a concentration of about
0.01 pg/mL to about
100 pg/mL in the composition. In further embodiments, the MiHA peptide(s)
is/are at a
concentration of about 0.2 pg/mL to about 50 pg/mL, about 0.5 pg/mL to about
10, 20, 30, 40 or
50 pg/mL, about 1 pg/mL to about 10 pg/mL, or about 2 pg/mL, in the
composition.
MiHA-specific TCRs and T lymphocytes
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
33
As noted above, cells such as APCs that express a MHC class I molecule (HLA-A2
or
HLA-B44) loaded with or bound to any one of, or any combination of, the MiHA
peptides defined
above, may be used for stimulating/amplifying CD8+ T lymphocytes in vivo or ex
vivo.
Accordingly, in another aspect, the present invention provides T cell receptor
(TCR)
molecules capable of interacting with or binding the above-mentioned MHC class
I
molecule/MiHA peptide complex, and nucleic acid molecules encoding such TCR
molecules,
and vectors comprising such nucleic acid molecules. A TCR according to the
present invention
is capable of specifically interacting with or binding a MiHA peptide loaded
on, or presented by,
a MHC class I molecule (HLA-A2 or HLA-B44), preferably at the surface of a
living cell in vitro or
in vivo. A TCR and in particular nucleic acids encoding a TCR of the invention
may for instance
be applied to genetically transform/modify T lymphocytes (e.g., CD8+ T
lymphocytes) or other
types of lymphocytes generating new T lymphocyte clones that specifically
recognizing a MHC
class I MiHA peptide complex. In a particular embodiment, T lymphocytes (e.g.,
CD8+ T
lymphocytes) obtained from a patient are transformed to express one or more
TCRs that
recognize MiHA peptide and the transformed cells are administered to the
patient (autologous
cell transfusion).
In another embodiment, the invention provides a T lymphocyte e.g., a CD8+ T
lymphocyte transformed/transfected by a vector or plasmid encoding a MiHA
peptide-specific
TCR. In a further embodiment the invention provides a method of treating a
patient with
autologous or allogenic cells transformed with a MiHA-specific TCR. In yet a
further
embodiment the use of a MiHA specific TCR in the manufacture of autologous or
allogenic cells
for treating of cancer is provided.
In some embodiments patients treated with the therapeutic compositions of the
invention are treated prior to or following treatment with allogenic stem cell
transplant (ASCL),
allogenic lymphocyte infusion or autologous lymphocyte infusion. Therapeutic
compositions of
the invention include: allogenic T lymphocytes (e.g., CD8+ T lymphocyte)
activated ex vivo
against a MiHA peptide; allogenic or autologous APC vaccines loaded with a
MiHA peptide;
MiHA peptide vaccines and allogenic or autologous T lymphocytes (e.g., CD8+ T
lymphocyte) or
lymphocytes transformed with a MiHA-specific TCR.
The method to provide T lymphocyte clones capable of recognizing an MiHA
peptide
according to the invention may be generated for and can be specifically
targeted to tumor cells
expressing the MiHA in a subject (e.g., graft recipient), for example an ASCT
and/or donor
lymphocyte infusion (DLI) recipient. Hence the invention provides a CD8+ T
lymphocyte
encoding and expressing a T cell receptor capable of specifically recognizing
or binding a MiHA
peptide/MHC class I molecule complex. Said T lymphocyte (e.g., CD8+ T
lymphocyte) may be a
recombinant (engineered) or a naturally selected T lymphocyte. This
specification thus provides
at least two methods for producing CD8+ T lymphocytes of the invention,
comprising the step of
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
34
bringing undifferentiated lymphocytes into contact with a MiHA peptide/MHC
class I molecule
complex (typically expressed at the surface of cells, such as APCs) under
conditions conducive
of triggering T cell activation and expansion, which may be done in vitro or
in vivo (i.e. in a
patient administered with a APC vaccine wherein the APC is loaded with a MiHA
peptide or in a
patient treated with a MiHA peptide vaccine). Alternatively, MiHA-specific or
targeted T
lymphocytes may be produced/generated in vitro or ex vivo by cloning one or
more nucleic
acids (genes) encoding a TCR (more specifically the alpha and beta chains)
that specifically
binds to a MHC class I molecule/MiHA complex (i.e. engineered or recombinant
CD8+ T
lymphocytes). Nucleic acids encoding a MiHA-specific TCR of the invention, may
be obtained
using methods known in the art from a T lymphocyte activated against a MiHA
peptide ex vivo
(e.g., with an APC loaded with a MiHA peptide); or from an individual
exhibiting an immune
response against peptide/MHC molecule complex. MiHA-specific TCRs of the
invention may be
recombinantly expressed in a host cell and/or a host lymphocyte obtained from
a graft recipient
or graft donor, and optionally differentiated in vitro to provide cytotoxic T
lymphocytes (CTLs).
The nucleic acid(s) (transgene(s)) encoding the TCR alpha and beta chains may
be introduced
into a T cells (e.g., from a subject to be treated or another individual)
using any suitable
methods such as transfection (e.g., electroporation) or transduction (e.g.,
using viral vector).
The engineered CD8+ T lymphocytes expressing a TCR specific for a MiHA may be
expanded
in vitro using well known culturing methods.
The present invention provides isolated CD8+ T lymphocytes that are
specifically
induced, activated and/or amplified (expanded) by a MiHA peptide (i.e., a MiHA
peptide bound
to MHC class I molecules expressed at the surface of cell). The present
invention also provides
a composition comprising CD8+ T lymphocytes capable of recognizing an MiHA
peptide
according to the invention (i.e., a MiHA peptide bound to MHC class I
molecules) and said MiHA
peptide.
In another aspect, the present invention provides a cell population or cell
culture (e.g.,
a CD8+ T lymphocyte population) enriched in CD8+ T lymphocytes that
specifically recognize a
MHC class I molecule/MiHA peptide complex as described herein. Such enriched
population
may be obtained by performing an ex vivo expansion of specific T lymphocytes
using cells such
as APCs that express MHC class I molecules loaded with e.g. presenting) one or
more of the
MiHA peptides disclosed herein. "Enriched" as used herein means that the
proportion of MiHA-
specific CD8+ T lymphocytes in the population is significantly higher relative
to a native
population of cells, i.e. which has not been subjected to a step of ex vivo-
expansion of specific T
lymphocytes. In a further embodiment, the proportion of MiHA-specific CD8+ T
lymphocytes in
the cell population is at least about 0.5%, for example at least about 1%,
1.5%, 2% or 3%. In
some embodiments, the proportion of MiHA-specific CD8+ T lymphocytes in the
cell population
is about 0.5 to about 10%, about 0.5 to about 8%, about 0.5 to about 5%, about
0.5 to about
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
4%, about 0.5 to about 3%, about 1% to about 5%, about 1% to about 4%, about
1% to about
3%, about 2% to about 5%, about 2% to about 4%, about 2% to about 3%, about 3%
to about
5% or about 3% to about 4%. Such cell population or culture (e.g., a CD8+ T
lymphocyte
population) enriched in CD8+ T lymphocytes that specifically recognizes a MHC
class I
5 molecule/peptide (MiHA) complex of interest may be used in MiHA-based cancer
immunotherapy, as detailed below.
In some embodiments, the population of MiHA-specific CD8+ T lymphocytes is
further
enriched, for example using affinity-based systems such as multimers of MHC
class I molecule
loaded (covalently or not) with the MiHA peptide defined above. Thus, the
present invention
10 provides a purified or isolated population of MiHA-specific CD8+ T
lymphocytes, e.g., in which
the proportion of MiHA-specific CD8+ T lymphocytes is at least 50%, 60%, 70%,
80%, 85%,
90% or 95%.
MiHA-based cancer immunotherapy
15 The MiHA peptide sequences identified herein may be used for the
production of
synthetic peptides to be used i) for in vitro priming and expansion of MiHA-
specific T cells to be
injected into transplant (AHCT) recipients and/or ii) as vaccines to boost the
graft-vs.-tumor
effect (GvTE) in recipients of MiHA-specific T cells, subsequent to the
transplantation.
The potential impact of the therapeutic methods provided by the present
invention,
20 MiHA-targeted cancer immunotherapy is significant. For hematologic
cancers (e.g., leukemia,
lymphoma and myeloma), the use of anti-MiHA T cells may replace conventional
AHCT by
providing superior anti-tumor activity without causing GvHD. It may benefit
many patients with
hematologic malignancy who cannot be treated by conventional AHCT because
their
risk/reward (GvHD/GVT) ratio is too high. Finally, since studies in mice have
shown that MiHA-
25 targeted immunotherapy may be effective for treatment of solid tumors,
MiHA-based cancer
immunotherapy may be used for MiHA-targeted therapy of non-hematologic
cancers, such as
solid cancers.
In embodiment, the cancer is leukemia including but not limited to acute
lymphoblastic
leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia
(CLL) chronic
30 myeloid leukemia (CML), Hairy cell leukemia (HCL), T-cell prolymphocytic
leukemia (T-PLL),
Large granular lymphocytic leukemia or Adult T-cell leukemia. In another
embodiment, the
cancer is lymphoma including but not limited to Hodgkin lymphoma (HL), non-
Hodgkin
lymphoma (NHL), Burkitt's lymphoma, Precursor T-cell leukemia/lymphoma,
Follicular
lymphoma, Diffuse large B cell lymphoma, Mantle cell lymphoma, B-cell chronic
lymphocytic
35 leukemia/lymphoma or MALT lymphoma. In a further embodiment, the cancer
is a myeloma
(multiple myeloma) including but not limited to plasma cell myeloma,
myelomatosis, and
Kahler's disease.
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
36
In another aspect, the present invention provides the use of a MiHA peptide of
the
present invention as a vaccine for treating cancer in a subject. In an
embodiment, the subject is
a recipient of MiHA-specific CD8+ T lymphocytes.
Accordingly, in another aspect, the present invention provides a method of
treating
cancer (e.g., of reducing the number of tumor cells, killing tumor cells),
said method comprising
administering (infusing) to a subject in need thereof an effective amount of
CD8+ T lymphocytes
recognizing (i.e. expressing a TCR that binds) a MHC class I molecule/MiHA
peptide complex
(expressed at the surface of a cell such as an APC). In an embodiment, the
method further
comprises administering an effective amount of the MiHA peptide, and/or a cell
(e.g., an APC
such as a dendritic cell) expressing MHC class I molecule loaded with the MiHA
peptide, to said
subject after administration/infusion of said CD8+ T lymphocytes. In yet a
further embodiment,
the method comprises administering to a subject in need thereof a
therapeutically effective
amount of a dendritic cell loaded with one or more MiHA peptides. In yet a
further embodiment
the method comprises administering to a patient in need thereof a
therapeutically effective
amount of a allogenic or autologous cell that expresses a recombinant TCR that
binds to a
MiHA peptide presented by a MHC class I molecule.
In another aspect, the present invention provides the use of CD8+ T
lymphocytes that
recognize a MHC class I molecule loaded with (presenting) a MiHA peptide for
treating cancer
(e.g., of reducing the number of tumor cells, killing tumor cells) in a
subject. In another aspect,
the present invention provides the use of CD8+ T lymphocytes that recognize a
MHC class I
molecule loaded with a MiHA peptide for the preparation/manufacture of a
medicament for
treating cancer (e.g., fir reducing the number of tumor cells, killing tumor
cells) in a subject.
In another aspect, the present invention provides CD8+ T lymphocytes that
recognize a
MHC class I molecule loaded with (presenting) a MiHA peptide for use in the
treatment of
cancer (e.g., for reducing the number of tumor cells, killing tumor cells) in
a subject.
In a further embodiment, the use further comprises the use of an effective
amount of a
MiHA peptide, and/or of a cell (e.g., an APC) that expresses a MHC class I
molecule loaded
with (presenting) a peptide of formula I, after the use of said MiHA-specific
CD8+ T lymphocytes.
In an embodiment, the subject infused or treated with MiHA-specific CD8 T-
cells has
received prior treatment with AHCT or donor lymphocyte infusions (i.e.
lymphocytes, including
T-cells, that have not been activated in vitro against a MiHA peptide
presented by a MHC class I
molecule. In a further embodiment, the cancer is a hematologic cancer, e.g.,
leukemia,
lymphoma and myeloma. In an embodiment, the cancer is leukemia.
Treatment and Donor Selection Methods
Allogenic therapeutic cells of the invention express a TCR that recognizes a
MiHA
peptide that is presented by a patient's (recipient's) tumor cells but not
presented by cells of the
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
37
donor. The invention provides a method of selecting an effective therapeutic
composition for a
patient having hematological cancer comprising: (a) obtaining a biological
sample from the
patient; (b) determining the presence or absence of one or more SNPs selected
from Table II;
(c) determining the expression of RNA or protein products corresponding to one
or more of the
SNPs provided in Table ll in a tumor sample from the patient. For treatment
with allogenic cells:
(a) a donor that does not express a genetic variant, corresponding to a MiHA
peptide (i.e. those
provided in Table ll herein) presented by MHC class I molecules expressed by
the recipient's
cancer cells is selected (b) lymphocytes are obtained from the donor and (c)
CD8+ T
lymphocytes specific for the presented MiHA peptide are prepared using the
methods provided
herein and administered to the patient. Alternatively allogenic cells obtained
from the selected
donor, one that does not express the MiHA of interest, can be genetically
transformed to
express a TCR against the MiHA of interest and administered to the patient.
For treatment with autologous cells, an autologous T lymphocyte expressing a
TCR
that recognizes a MiHA presented by MHC class I molecules present on the cell
surface of a
patient's cancer cells is administered. The invention provides a method of
selecting a T
lymphocyte therapy for a patient comprising: (a) obtaining a biological sample
from the patient;
(b) determining the presence or absence of one or more SNPs selected from
Table II; (c)
determining the expression of RNA or protein products corresponding to one or
more of the
SNPs provided in Table ll in a tumor sample from the patient.
To determine which variant of a given MiHA that should be used in the
treatment of a
subject (e.g., using MiHA No. 1 as an example, to determine which of SED ID
NO: 80 or 81
should be used), the allelic variant expressed by the subject should be first
determined. The
amino acid substitutions in the proteins as well as the nucleotide
substitutions in the transcripts
corresponding to the novel MiHAs described herein (Table II) may be easily
identified by the
skilled person, for example using the information provided in public
databases. For example,
Table ll includes the reference/identification No. for MiHAs in the dbSNP
database, which
provides detailed information concerning the variations at the genomic,
transcript and protein
levels. Based on this information, the determination of the variant
(polymorphism or single
nucleotide polymorphism (SNP)) expressed by the subject may be readily
performed at the
nucleic acid and/or protein level on a sample by a number of methods which are
known in the
art. Table ll also includes the reference ID in the Ensembl database for the
genes from which
the MiHA peptides are derived.
Examples of suitable methods for detecting alterations at the nucleic acid
level include
sequencing the relevant portion (comprising the variation) of the nucleic acid
of interest (e.g., a
mRNA, cDNA or genomic DNA encoding the MiHAs), hybridization of a nucleic acid
probe
capable of specifically hybridizing to a nucleic acid of interest comprising
the polymorphism (the
first allele) and not to (or to a lesser extent to) a corresponding nucleic
acid that do not comprise
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
38
the polymorphism (the second allele) (under comparable hybridization
conditions, such as
stringent hybridization conditions), or vice-versa; restriction fragment
length polymorphism
analysis (RFLP); Amplified fragment length polymorphism PCR (AFLP-PCR);
amplification of a
nucleic acid fragment using a primer specific for one of the allele, wherein
the primer produces
an amplified product if the allele is present and does not produce the same
amplified product
when the other allele is used as a template for amplification (e.g., allele-
specific PCR). Other
methods include in situ hybridization analyses and single-stranded
conformational
polymorphism analyses. Further, nucleic acids of interest may be amplified
using known
methods (e.g., polymerase chain reaction [PCR]) prior to or in conjunction
with the detection
methods noted herein. The design of various primers for such amplification is
known in the art.
The nucleic acid (mRNA) may also be reverse transcribed into cDNA prior to
analysis.
Examples of suitable methods for detecting alterations/polymorphisms at the
polypeptide level include sequencing of the relevant portion (comprising the
variation) of the
polypeptide of interest, digestion of the polypeptide followed by mass
spectrometry or HPLC
analysis of the peptide fragments, wherein the variation/polymorphism of the
polypeptide of
interest results in an altered mass spectrometry or HPLC spectrum; and
immunodetection using
an immunological reagent (e.g., an antibody, a ligand) which exhibits altered
immunoreactivity
with a polypeptide comprising the alteration (first allele) relative to a
corresponding native
polypeptide not comprising the alteration (second allele), for example by
targeting an epitope
comprising the amino acid variation. Immunodetection can measure the amount of
binding
between a polypeptide molecule and an anti-protein antibody by the use of
enzymatic,
chromodynamic, radioactive, magnetic, or luminescent labels which are attached
to either the
anti-protein antibody or a secondary antibody which binds the anti-protein
antibody. In addition,
other high affinity ligands may be used. Immunoassays which can be used
include e.g. ELISAs,
Western blots, and other techniques known to those of ordinary skill in the
art (see Harlow and
Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press,
Cold Spring
Harbor, N.Y., 1999 and Edwards R, Immunodiagnostics: A Practical Approach,
Oxford
University Press, Oxford; England, 1999).
All these detection techniques may also be employed in the format of
microarrays,
protein-arrays, antibody microarrays, tissue microarrays, electronic biochip
or protein-chip
based technologies (see Schena M., Microarray Biochip Technology, Eaton
Publishing, Natick,
Mass., 2000).
In one embodiment the invention provides a method of selecting an effective
therapeutic composition for a patient comprising: (a) isolating MHC class I
presented peptides
from hematologic cancer cells from the patient; and (b) identifying the
presence or absence of
one or more MiHA peptides depicted in Table I among said MHC class I presented
peptides. In
a further embodiment, the identification of the presence or absence of the one
or more MiHA
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
39
peptides depicted in Table I is performed by mass spectrometry and/or using an
antibody
detection reagent that is selective for the one or more MiHA peptides.
Detecting or identifying
MiHA peptides using mass spectrometry can be performed using methods known in
the art such
as those described in PCT publication No. W02014/026277. Mass spectrometry
(MS)
sequencing of MiHA peptides presented by MHC class I molecules, which have
been isolated
from a sample of cancer cells, involves comparing a MS spectra obtained for an
isolated and
digested peptide to spectra computed in silico for a MiHA peptide.
Therapeutic allogenic T lymphocytes of the present invention, for treating a
patient with
cancer, target MHC class I molecules presenting one or more MiHA peptides that
is/are
expressed by cancer cells in the patient but not expressed by the donor's
cells. As such,
selecting an appropriate donor for generating allogenic T lymphocytes of the
invention involves
genotyping candidate donors for the presence or absence of one or more single
nucleotide
polymorphisms provided in Table II.
In one embodiment the invention provides a method of selecting an effective
immunotherapy treatment (i.e. MHC class I molecule/MiHA peptide complex
target) for a patient
with cancer comprising: determining the presence of MiHA peptides presented by
MHC class I
molecules in tumor cells from the patient.
In another embodiment the invention provides a method of screening candidate
allogenic cell donors for a patient comprising determining the presence or
absence of one or
more SNPs selected from those provided in Table II in a biological sample from
the donor. In
an embodiment, the presence or absence of a SNP corresponding to a MiHA
peptide known to
be presented by MHC class I molecule in cancer cells obtained from a patient
is determined in
candidate donors. In a further embodiment, biological samples obtained from
candidate
allogenic donors are genotyped to determine the presence or absence of one or
more SNPs
known to be carried by a patient, wherein the SNPs detected are selected from
those provided
in Table II.
In a further embodiment the invention provides a genotyping system comprising
a
plurality of oligonucleotide probes conjugated to a solid surface for
detection of a plurality of
SNPs selected from Table II.
For example, to determine which variant of MiHA No. 1 (SEQ ID Nos. 80 or 81)
should
be used in the treatment of a subject, it should be determined on a sample
from the subject
using any suitable method (sequencing, etc.) whether (i) a transcript from the
ANKRD13A gene
comprises a T or C at a position corresponding to position 1680 of Ensembl
Transcript ID No.
ENST0000261739 (ENSG00000076513); (ii) the nucleotide corresponding to
position
110036265 of chromosome 12 in human genome assembly GRCh38 is C or T; and/or
(iii) an
ANKRD13A polypeptide comprises a leucine or proline residue at a position
corresponding to
position 505 of the polypeptide encoded by Ensembl Transcript ID No.
ENST0000261739
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
(ENSG00000076513). If (i) the transcript from the ANKRD13A gene comprises a T
at a position
corresponding to position 1680 of Ensembl Transcript ID No. ENST0000261739;
(ii) the
nucleotide corresponding to position 110036265 of chromosome 12 in human
genome
assembly GRCh38 is T; and/or (iii) the ANKRD13A polypeptide comprises a
leucine residue at a
5 position corresponding to position 505 of the polypeptide encoded by
Ensembl Transcript ID No.
ENST0000261739, MiHA variant of SEQ ID No. 80 (SLLESSRSQEL) should be used.
Alternatively, if (i) the transcript from the ANKRD13A gene comprises a C at a
position
corresponding to position 1680 of Ensembl Transcript ID No. EN5T0000261739;
(ii) the
nucleotide corresponding to position 110036265 of chromosome 12 in human
genome
10 assembly GRCh38 is C; and/or (iii) the ANKRD13A polypeptide comprises a
proline residue at a
position corresponding to position 505 of the polypeptide encoded by Ensembl
Transcript ID No.
ENST0000261739, MiHA variant of SEQ ID No. 81 (SLLESSRSQEP) should be used.
The
same approach may be applied to determine which variant of any of MiHAs Nos. 2-
5, 7-25, 27-
30 and 32-84 should be used in a given subject.
15 MiHAs Nos. 34 and 35 may only be used in male subjects (since the
encoding gene is
located on chromosome Y, the MiHA is only expressed in male subjects).
In an embodiment, the above-mentioned CD8+ T lymphocytes are in vitro or ex
vivo
expanded CD8+ T lymphocytes, as described above. Expanded CD8+ T lymphocytes
may be
obtained by culturing primary CD8+ T lymphocytes (from an allogenic donor)
under conditions
20 permitting the proliferation (amplification) and/or differentiation of
the CD8+ T lymphocytes. Such
conditions typically include contacting the CD8+ T lymphocytes with cells,
such as APCs,
expressing at their surface the MiHA peptide/MHC complexes of interest, in the
presence of a
suitable medium (medium for hematopoietic/Iymphoid cells, e.g., X-VIVOTm15 and
AIM-V )
growth factors and/or cytokines such as IL-2, IL-7 and/or IL-15 (see, e.g.,
Montes etal., Clin Exp
25 Immunol. 2005 Nov;142(2):292-302). Such expanded CD8+ T lymphocytes are
then
administered to the recipient, for example through intravenous infusion.
Methods and conditions
for amplifying and preparing antigen-specific CD8+ T lymphocytes for adoptive
immunotherapy
are disclosed, for example, in DiGiusto et al., Cytotherapy 2007; 9(7): 613-
629 and Bollard et
al., Cytotherapy. 2011 May; 13(5): 518-522). Standard Operating procedures
(SOPs) for
30 amplifying antigen-specific CD8+ T lymphocytes are available from the
Center for Cell and Gene
Therapy, Baylor College of Medicine, Texas Children's Hospital, The Methodist
Hospital,
Houston, Texas, USA (see Sili et al., Cytotherapy. 2012 Jan; 14(1): 7-11,
Supplementary
Material).
In an embodiment, the subject (recipient) is an allogeneic stem cell
transplantation
35 (ASCT) or donor lymphocyte infusion (DLI) recipient.
In another aspect, the present invention provides a method of expanding CD8+ T
lymphocytes (e.g., for adoptive T-cell immunotherapy), said method comprising
(a), culturing
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
41
CD8+ T lymphocytes from a first individual not expressing a variant of a MiHA
peptide in the
presence of cells expressing a MHC class I molecule of the HLA-A2 and/or HLA-
B44 allele
loaded with said variant of the MiHA peptide, under conditions suitable for
CD8+ T lymphocyte
expansion.
In another aspect, the invention provides a method of producing/manufacturing
cells for
cellular immunotherapy comprising: culturing human lymphocytes in the presence
of APC
comprising a MiHA peptide presented by a MHC class I molecule, wherein the MHC
class I
molecule is of the HLA-A2 or ALA-B44 subtype. The human T lymphocyte used in
this method
is an allogenic cell i.e. a cell obtained from a donor being manufactured for
treating a recipient
with an allogenic cell.
In another aspect, the invention provides a method of producing/manufacturing
cells for
cellular immunotherapy comprising: (a) obtaining lymphocytes (e.g., T
lymphocytes) from a
cultured cell line and (b) culturing the cells in the presence of APC
comprising a MHC class I
molecule/MiHA peptide complex wherein the MHC class I molecule is a HLA-A2 or
ALA-B44
subtype. The human T lymphocyte used in the method is preferably an allogenic
cell i.e. a cell
obtained from a donor being manufacture for treating a recipient with an
allogenic cell.
In a further embodiment, the invention provides a method of
producing/manufacturing
cells for cellular immunotherapy comprising: (a) obtaining cells from a donor,
e.g., a patient
having a hematopoietic cancer (e.g., leukemia) or a healthy individual, for
example by
leukapheresis, and (b) transforming the cells with a recombinant TCR that
binds to a MHC class
I molecule/MiHA peptide complex.
In a further embodiment, the invention provides a method of manufacturing
cells for
cellular immunotherapy comprising transforming a human cell line with a
recombinant TCR that
binds with to a MHC class I molecule/MiHA peptide complex as defined herein.
In another aspect, the present invention provides a method of expanding CD8+ T
lymphocytes for adoptive 1-cell immunotherapy, said method comprising (a)
determining which
variant of any of MiHA Nos. 1-93, preferably MiHAs 7, 8, 10, 14-15, 20-21, 32,
33, 35, 39-47,
49-50, 66, 70-71, 76, 78, 81, 84 and 90 is expressed by a subject (recipient),
culturing CD8+ T
lymphocytes from a candidate donor in the presence of cells expressing a MHC
class I molecule
of the HLA-A2 and/or HLA-B44 allele loaded with the MiHA variant expressed by
the subject,
under conditions suitable for CD8+ T lymphocyte expansion, wherein said
candidate donor does
not express the MiHA variant (expressed by the subject (recipient)).
In another aspect, the invention provides a method of selecting a therapeutic
approach
for a patient having leukemia: (a) detecting the presence of a MiHA peptide
presented by a
MHC class I molecule expressed in leukemic cells obtained from the patient;
and (b)
determining the presence or absence of a SNP corresponding to the MiHA peptide
detected in
step (a), as indicated in Table II, in biological samples obtained from
candidate donors.
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
42
In another aspect, the invention provides a method of preparing a therapeutic
composition for a patient having leukemia: (a) detecting the presence of a
MiHA peptide
presented by a MHC class I molecule expressed in leukemic cells obtained from
the patient; (b)
obtaining lymphocytes from the patient by leukapheresis, and (c) transforming
said lymphocytes
with a TCR that recognizes the presented MiHA peptide detected in step (a).
In another aspect, the invention provides a method of preparing a therapeutic
composition for a patient having leukemia: (a) genotyping the patient to
determine the presence
of a plurality of SNPs selected from Table II; (b) determining the presence of
one of the SNPs in
the patient (c) obtaining cells from the patient by leukapheresis, and (d)
incubating said cells
with a APC expressing a MHC class I molecule/MiHA peptide complex, comprising
a MiHA
peptide that contains the polymorphism encoded by the SNP present in said
patient.
Again using MiHA No. 1 (SEQ ID NO: 79) as a representative example to
illustrate the
method, if it is determined that in a sample from the subject: (i) the
transcript from the
ANKRD13A gene comprises a T at a position corresponding to position 1680 of
Ensembl
Transcript ID No. ENST0000261739; (ii) the nucleotide corresponding to
position 110036265 of
chromosome 12 in human genome assembly GRCh38 is T; and/or (iii) the ANKRD13A
polypeptide comprises a leucine residue at a position corresponding to
position 505 of the
polypeptide encoded by Ensembl Transcript ID No. ENST0000261739, the CD8+ T
lymphocytes
from the candidate donor are cultured in the presence of cells expressing a
MHC class I
molecule of the HLA-A2 allele loaded with MiHA variant of SEQ ID No. 80
(SLLESSRSQEL)
under conditions suitable for CD8+ T lymphocyte expansion. Alternatively, if
it is determined that
in a sample from the subject: (i) the transcript from the ANKRD13A gene
comprises a C at a
position corresponding to position 1680 of Ensembl Transcript ID No.
ENST0000261739; (ii) the
nucleotide corresponding to position 110036265 of chromosome 12 in human
genome
assembly GRCh38 is C; and/or (iii) the ANKRD13A polypeptide comprises a
proline residue at a
position corresponding to position 505 of the polypeptide encoded by Ensembl
Transcript ID No.
ENST0000261739, the CD8+ T lymphocytes from the candidate donor are cultured
in the
presence of cells expressing a MHC class I molecule of the HLA-A2 allele
loaded with MiHA
variant of SEQ ID No. 81 (SLLESSRSQEP) under conditions suitable for CD8+ T
lymphocyte
expansion. The same approach may be applied to any of MiHAs Nos. 2-93 defined
herein.
In an embodiment, the present invention provides a method of treating cancer,
said
method comprising (i) expanding CD8+ T lymphocytes recognizing a MHC class I
molecule
loaded with a peptide of formula I for adoptive T-cell immunotherapy according
to the method
defined above; and (ii) administering (infusing) to a subject in need thereof
an effective amount
of the expanded CD8+ T lymphocytes. In one embodiment, the method further
comprises
administering an effective amount of the peptide of formula I, and/or a cell
(e.g., an APC)
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
43
expressing MHC class I molecule loaded with a MiHA peptide of formula I, to
said subject after
administration/infusion of said CD8+ T lymphocytes.
In embodiment, the above-mentioned cancer comprises tumor cells expressing the
genes encoding MiHAs Nos. 1-93, preferably MiHAs 7, 8, 10, 14-15, 20-21, 32,
33, 35, 39-47,
49-50, 66, 70-71, 76, 78, 81, 84 and 90 set forth in Table I.
Although the present invention has been described hereinabove by way of
specific
embodiments thereof, it can be modified, without departing from the spirit and
nature of the
subject invention as defined in the appended claims. In the claims, the word
"comprising" is
used as an open-ended term, substantially equivalent to the phrase "including,
but not limited
to". The singular forms "a", "an" and "the" include corresponding plural
references unless the
context clearly dictates otherwise.
MODE(S) FOR CARRYING OUT THE INVENTION
The present invention is illustrated in further details by the following non-
limiting
examples.
Example 1: Materials and Methods
The MiHAs were identified according to the method/strategy described in PCT
publication No. WO 2014/026277 and (3). A schematic overview of the procedure
is depicted in
FIG. 1.
Cell culture. Peripheral blood mononuclear cells (PBMCs) were isolated from
blood
samples of 6 female and 7 male volunteers expressing at least one of the
following two
common alleles HLA-A*02:01 and HLA-B*44:03. Epstein-Barr virus (EBV)-
transformed B
lymphoblastoid cell lines (B-LCLs) were derived from PBMCs with Ficoll-PaqueTM
Plus
(Amersham) as previously described (Tosato and Cohen, 2007). Established B-
LCLs were
maintained in RPM! 1640 medium supplemented with 10% fetal bovine serum, 25 mM
of
HEPES, 2 mM L-glutamine and penicillin-streptomycin (all from Invitrogen).
DNA extraction. Genomic DNA was extracted from 5 million B-LCLs using the
PureLinkTM Genomic DNA Mini Kit (Invitrogen ) according to the manufacturer's
instructions.
DNA was quantified and quality-assessed using the Taqman RNase P Detection
Reagents Kit
(Life Technologies ).
HLA typing. High-resolution HLA genotyping was performed using 500 ng of
genomic
DNA at the Maisonneuve-Rosemont Hospital.
Preparation of genomic DNA libraries. Genomic libraries were constructed from
200 ng
of genomic DNA using the Ion AmpliSeqTM Exome RDY Library Preparation Kit
(Life
Technologies ) following the manufacturer's protocol. This included the
following steps:
amplification of targets, partial digestion of primer sequences, ligation of
Ion XpressTM barcode
adapters to the amplicons, purification of the library using AMPure XP
reagent (Beckman
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
44
Coulter ) and quantification of the unamplified library by qPCR. Library
templates were then
prepared and loaded onto Ion Proton TM I chips using the Ion P1TM IC 200 kit
and the Ion ChefTM
System.
Exome sequencing and variant calling. Two exome libraries were sequenced per
chip
on an Ion ProtonTM Sequencer using the default parameters of AmpliSeqTM exome
libraries.
Variant calling was done using the Torrent Variant Caller plugin with the
"germ Line Proton ¨
Low Stringency" parameter of the Ion reporter Software.
RNA extraction. Total RNA was isolated from 5 million B-LCLs using TRizol RNA
reagent (Life Technologies ) including DNase I treatment (Qiagen ) according
to the
manufacturer's instructions. Total RNA was quantified using the NanoDropTM
2000 (Thermo
Scientific ) and RNA quality was assessed with the 2100 BioanalyzerTM (Agilent
Technologies ).
Preparation of transcriptome libraries. Libraries were generated from 1 pg of
total RNA
using the TruSeqTm RNA Sample Prep Kit (v2) (RS-930-1021, Illumina ) following
the
manufacturer's protocol. Briefly, poly-A mRNA was purified using poly-T oligo-
attached
magnetic beads using two rounds of purification. During the second elution of
the poly-A RNA,
the RNA was fragmented and primed for cDNA synthesis. Reverse transcription
(RT) of the first
strand was done using random primers and SuperScriptTM II (InvitroGene ). A
second round of
RT was also done to generate a double-stranded cDNA, which was then purified
using
Agencourt AMpureTm XP PCR purification system (Beckman Coulter ). End repair
of
fragmented cDNA, adenylation of the 3' ends and ligation of adaptors were done
following the
manufacturer's protocol. Enrichment of DNA fragments containing adapter
molecules on both
ends was done using 15 cycles of PCR amplification and the Illumina PCR mix
and primers
cocktail.
Whole transcriptome sequencing (RNA-Seq). Paired-end (2 x 100 bp) sequencing
was
performed using the Illumina HiSeq2000TM machine running TruSeq Tm v3
chemistry. Cluster
density was targeted at around 600-800k clusters/mm2. Two transcriptomes were
sequenced
per lane (8 lanes per slide). Details of the Illumina sequencing technologies
can be found at
http://www.illumina.com/applications/detail/sequencing/dna sequencing.ilmn.
Read mapping. Sequence data were mapped to the human reference genome (hg19,
UCSC) using the !lumina Casava TM 1.8.1 and the Eland Tm v2 mapping softwares.
First, the *.bc1
files were converted into compressed FASTQ files, following by demultiplexing
of separate
multiplexed sequence runs by index. Then, single reads were aligned to the
human reference
genome including the mitochondrial genome using the multiseed and gapped
alignment
method. Reads that mapped at 2 or more locations (multireads) were not
included in further
analyses. An additional alignment was done against splice junctions and
contaminants
(ribosomal RNA).
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
Identification of single nucleotide variations in the transcriptome. First,
the list of all
single nucleotide variations observed between the reference genome (GRCh37.p2,
NCB!) and
the sequenced transcriptome of each of the individuals was retrieved. This was
done using the
SNP calling program Casava TM v1.8.2 from
!lumina
5
(http://support.illumina.com/sequencing/sequencing software/casava.ilmn).
Only high
confidence single nucleotide variations (Qmax_gt value>20) and that were
observed in at least
3 reads (coverage 3) were considered. SNVs with Qmax_gt value below this
threshold were
assigned with the reference base instead. This strategy was used to identify
single nucleotide
variations at the transcript level between each of the individuals and the
reference genome.
10 In
silico translated transcriptome. The sequences containing the identified
single
nucleotide variations of each individual were further processed. For each
sequence, all
transcripts reported in Ensembl
(http://useast.ensembl.org/info/data/ftp/index.html, Flicek et aL,
Ensembl 2012, Nucleic Acids Research 2012 40 Database issue:D84-D90) were
retrieved and
in silico translated into proteins using an in-house software pyGeno version
(python package
15
pyGeno 1.1.7, https://pypi.python.org/pypi/pyGeno/1.1.7), Granados et al.,
2012 (PMID:
22438248)). The in silico translated transcriptomes included cases in which
more than one non-
synonymous polymorphism was found for a given position. Considering that most
MAPs have a
maximum length of 11 amino acids (33 bp), the existence of a heterozygous
position could lead
to MiHA variants in a window of 21(66 bp) amino acids centered at each ns-SNP.
When a
20
window contained more than one ns-SNP, all possible combinations were
translated. The
number of combinations affected by one ns-SNP was limited to 10,240 to limit
the size of the
file. In this way, a list of all possible sequences of at most 11 amino acids
affected by ns-SNPs
was obtained and included in the individual-specific protein databases, which
were further used
for the identification of MAPs.
25 Mass
spectrometry and peptide sequencing. 3 to 4 biological replicates of 5-6x108
exponentially growing B-LCLs were prepared from each individual. MHC class I-
associated
peptides were released by mild acid treatment, pretreated by desalting with an
HLB cartridge
and filtered with a 3,000 Da cut-off column as previously described (Caron et
al. 2011 (PM ID:
21952136)). Samples were further processed according to two different methods.
In the first
30
method, samples were vacuum dried, resuspended in SCX Reconstitution Solution
(Protea )
and separated into six fractions using SCX spintips (Protea ) and an ammonium
formate buffer
step gradient (50, 75, 100, 300, 600, 1500 mM). Vacuum dried fractions were
resuspended in
5% acetonitrile, 0.2% formic acid and analyzed by LC¨MS/MS using an Eksigent
LC system
coupled to a LTQ-Orbitrap ELITETm mass spectrometer (Thermo Electron ).
Peptides were
35
separated on a custom C18 reversed phase column (pre-column: 0.3 mm i.d. x 5
mm, analytical
column: 150 pm i.d. x 100 mm; Jupiter C18 3 pm 300A) using a flow rate of 600
nUmin and a
linear gradient of 5-40% aqueous ACN (0.2% formic acid) in 56 min. Full mass
spectra were
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
46
acquired with the Orbitrap analyzer operated at a resolving power of 60,000
(at m/z 400).
Mass calibration used an internal lock mass (protonated (Si(CH3)20))6; m/z
445.120029) and
mass accuracy of peptide measurements was within 5 ppm. MS/MS spectra were
acquired at
higher energy collisional dissociation with normalized collision energy of 28.
Up to ten precursor
ions were accumulated to a target value of 50,000 with a maximum injection
time of 100 ms and
fragment ions were transferred to the Orbitrap analyzer operating at a
resolution of 60,000 at
m/z 400. In the second method, samples were split into two identical technical
replicates
following the 3,000 Da filtration step and vacuum-dried. One technical
replicate was
resuspended in 3% acetonitrile, 0.2% formic acid and analyzed by LC¨MS/MS
using an EASY-
nLC ll system coupled to a QExactiveTM Plus mass spectrometer (Thermo
Scientific ).
Peptides were separated on a custom C18 reversed phase column as in the first
method, using
a flow rate of 600 nl/min and a linear gradient of 3-25% aqueous ACN (0.2%
formic acid) in 146
min followed by 25-40% in 5 min. Full mass spectra were acquired with the
Orbitrap analyzer
operated at a resolving power of 70,000 (at m/z 400). Mass calibration used an
internal lock
mass (protonated (Si(CH3)20))6; m/z 445.120029) and mass accuracy of peptide
measurements
was within 5 ppm. MS/MS spectra were acquired at higher energy collisional
dissociation with
normalized collision energy of 25. Up to twelve precursor ions were
accumulated to a target
value of 1,000,000 with a maximum injection time of 200 ms and fragment ions
were transferred
to the Orbitrap analyser operating at a resolution of 17,500 at m/z 400.
MS/MS sequencing and peptide clustering. Database searches were performed
against databases specific to each individual (see 'in silico-generated
proteome and
personalized databases' section) using PEAKS 7 (Bioinformatics Solutions Inc.,
http://www.bioinfor.com/). Mass tolerances for precursor and fragment ions
were set to 5 p.p.m.
and 0.02 Da, respectively. Searches were performed without enzyme specificity
and with
variable modifications for cysteinylation, phosphorylation (Ser, Thr and Tyr),
oxidation (Met) and
deamidation (Asn, Gln). Raw data files were converted to peptide maps
comprising m/z values,
charge state, retention time and intensity for all detected ions above a
threshold of 30,000
counts. Using in-house software (Proteoprofile) (Granados et al. 2014),
peptide maps
corresponding to all identified peptide ions were aligned together to
correlate their abundances
across sample replicates. PEAKS decoy-fusion approach was used to calculate
the false
discovery rate of quantified unique peptide sequences. The highest scored
MS/MS spectra of
MHC class I peptides detected in at least one of the individuals were
validated manually, using
XcaliburTM software version 2.2 SP1.48 (Thermo Scientific ).
Selection of MiHAs. Peptides were filtered by their length and those peptides
with the
canonical MAP length (typically 8-14 mers) were kept. The predicted binding
affinity (IC50) of
peptides to the allelic products was obtained using NetMHC version 3.4
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
47
(http://www.cbs.dtu.dk/services/NetMHC/, Lundegaard et al., 2008 (PMID:
18413329)). Peptides
with an IC50 below 5,000 nM were considered as HLA binders.
MiHAs were selected according to the following criteria:
i) Presence of a reported non-synonymous SNP (nsSNP) in the peptide-coding
region (a total of 6,773 polymorphic peptides) of the individuals leading to
surface
expression of the corresponding peptide(s). These constitute MiHA differences
between the individuals and other individuals harboring the alternate allele
for the
reported SNP.
ii) Unambiguous origin of the MiHA. Hence, the MiHA has a single genetic
origin in
the individual's genome.
iii) The MiHA does not derive from immunoglobulins or HLA class I or class ll
genes
since these genes are highly polymorphic and very variable between
individuals.
iv) The MiHA has a reported minor allele frequency (MAF) of at least 0.05
according
to the dbSNP database build 138 (NCB!) and/or the NHLBI Exome Sequencing
Project (ESP).
The RNA (cDNA) and DNA sequences encoding MiHAs were manually inspected using
the Integrative Genomics Viewer v2.3.25 (The Broad Institute). The UCSC Repeat
Masker track
was included to discard candidates that corresponded to repetitive regions.
Determination of allele frequency. The minor allele frequency (MAF) of each ns-
SNP
was obtained from the dbSNP database build 138 (NCB!) and/or the NHLBI Exome
Sequencing
Project (ESP). A definition of MAF can be found
here:
(http://www.ncbi.nlm.nih.gov/projects/SNP/docs/rs attributes. html. Briefly,
dbSNP is reporting
the minor allele frequency for each rs included in a default global
population. Since this is being
provided to distinguish common polymorphism from rare variants, the MAF is
actually the
second most frequent allele value. In other words, if there are 3 alleles,
with frequencies of 0.50,
0.49, and 0.01, the MAF will be reported as 0.49. The default global
population is 1000Genome
phase 1 genotype data from 1094 worldwide individuals, released in the May
2011 dataset.
MS/MS validation of MiHA sequences. The highest scored MS/MS spectra of all
candidate MiHAs detected in at least one of the individuals were validated
manually, using
XcaliburTM software version 2.2 SP1.48 (Thermo Scientific ). MS/MS spectra of
the selected
MiHAs were further validated using synthetic MiHA versions synthesized by
Genscript.
Subsequently, 250 ¨ 500 fmol of each peptide were injected in the LTQ-Orbitrap
ELITETm or the
Q-Exactive TM Plus mass spectrometer using the same parameters as those used
to analyze the
biological samples.
Determination of the tissue distribution of gene expression. Allogeneic T
cells can react
against a multitude of host MiHAs expressed elsewhere than in
hematopoietic/Iymphoid organs
and induce GVHD. Therefore, to avoid GVHD MiHA expression should not be
ubiquitous.
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
48
Unfortunately, current technical limitations prevent from experimentally
assessing MiHA
expression in these tissues by mass spectrometry. As an alternative, it was
previously shown
that MAPs preferentially derive from abundant transcripts (Granados et al.
Blood 2012). Thus,
the level of expression of transcripts coding for MiHAs could be used as an
indicator of MiHAs
expression. Publicly available data from Fagerberg etal., Mol Cell Proteomics
2014 13: 397-406
were used, which is part of The Human Project Atlas (THPA)
(http://www.proteinatlas.orq/tissue,
Uhlen et al (2010). Nat Biotechnol. 28(12):1248-50), listing the expression
profiles of human
genes for 27 tissues. From this data, the expression level of genes coding for
the identified
MiHAs was obtained. Genes were then classified as "ubiquitous" if expressed in
27 tissues with
a "Fragments Per Kilobase of exons per Million mapped reads (FPKM)" > 10 or as
"not
ubiquitous" if not expressed with a FPKM > 10 in all 27 tissues. Also, these
data were used to
calculate the ratio of MiHA genes expression in the bone marrow compared to
the skin. Of note,
the bone marrow samples used by from Fagerberg et al. (supra) were FicollTm-
separated
preparations in which non-hematopoietic components of stroma, adipose cells,
bone and
vessels, as well as large portions of the fully differentiated erythropoietic
and myelopoietic
populations had been removed
(http://www.proteinatlas.org/humanproteome/bone+marrow).
Reads Per Kilobase per Million mapped reads (RPKM) values of MiHA-coding genes
in AML
samples were obtained from the TCGA Data Portal version 3.1.6. AML data
included 128
samples of different subtypes: 12 MO, 36 Ml, 29 M2, 12 M3, 23 M4, 14 M5, 2 not
classified.
Values were converted to Logio(1,000 RPKM +1) for visualization purposes. Mean
values were
calculated using the 128 AMLs, expect for the Y chromosome-encoded UTY gene,
for which
only 65 male samples were considered.
Cumulative number of identified MiHAs per individual. A custom software tool
was used
to estimate the cumulative number of HLA-A*02:01 or HLA-B*44:03-associated
MiHAs expected
for each additional individual studied. Since this number is influenced by the
MiHAs present in
each individual and by the order in which individuals are analyzed, we
exhaustively listed the
number of newly identified MiHAs expected for each additional individual
studied in all
combinations and permutations of groups of studied individuals. Then, we
computed the
average number of MiHAs for each number of studied individuals. To approximate
the
cumulative number of MiHAs for up to 20 individuals, a predictive curve was
mapped on the
data points. The curve was fitted on a function using the curve_fit tool from
the "optimize"
module of the "scipy" Python library (Jones E, Oliphant E, Peterson P, et al.
SciPy: Open
Source Scientific Tools for Python, 2001-, http://www.scipy.org/). The
following equation was
used to represent the cumulative number of identified MiHAs:
a x x
_
b + x
Frequency of therapeutic MiHA mismatches. In order to estimate the number of
therapeutic MiHA mismatches, a bioinformatic simulation approach was used. For
each ns-SNP
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
49
encoding the 39 optimal MiHAs, the reported alleles were retrieved from the
European-
American population of the Exome Sequencing Project (ESP) or, if not
available, from the
European population of "The 1,000 Genomes Project"
(http://www.1000genomes.org/). Next,
the alleles were categorized from a peptide perspective as `dominant` if the
MiHA was detected
by MS or known to be immunogenic, or as `recessive' if the MiHA was neither
detected by MS
nor shown to be immunogenic. Of note, in some loci both alleles were
codominant. It was
assumed that the presence of a dominant allele always leads to the surface
expression of the
MiHA. In the case of overlapping MiHAs deriving from the same ns-SNP, the MiHA
locus was
considered only once. In this simulation, it was also assumed that MiHA-coding
SNPs are
independent events. In the case of Y chromosome-derived MiHAs (absent in
females), a
therapeutic mismatch occurred in all male recipient/female donor pairs. Based
on the reported
minor allele frequencies (MAFs), the allele frequency of the `dominant' or of
the `recessive'
MiHA was determined in all MiHA-coding loci. Assuming a female/male ratio of
1:1, 1 x 106
unrelated donor/recipient pairs were randomly generated and virtually
genotyped using
increasing subsets (1 to 30) of this ranked list of MiHAs. Thus, one
population was generated
for each MiHA subset. The MAF of each MiHA was used as a probability to
generate each
individual's maternal and paternal MiHA alleles. For each MiHA subset tested,
this procedure
resulted in two sets of MiHA alleles (or MiHAs haplotypes) per individual. The
number of MiHA
mismatches found in each pair was determined and if at least one mismatch was
achieved, a
therapeutic mismatch was called. The same procedure was used for the related
pairs, except
that the sampling population corresponded to the progeny of a parental
population and was
generated according to Mendelian inheritance. This procedure was repeated 1 x
106 times for
both related and unrelated pairs.
Statistical analyses and data visualization. Unless otherwise stated, analyses
and
figures were performed using the RStudioTM version 0.98.1091, R version 3.1.2
and Prism TM
version 5.0d software. The Wilcoxon rank sum test was used to compare the
polymorphic index
distribution of exons and exon-exon junctions, or of MiHA-coding genes and
that of genes
coding for non-polymorphic MAPs. The gplots package in R was used to perform
hierarchical
clustering and heatmaps of MiHA genes expression in different AML subtypes.
Mean
expression of MiHA genes among AML subtypes was compared using ANOVA followed
by
Tukey's multiple-comparison test.
Determination of the immunogenicity of the identified MiHAs. T cells and
monocytes
were purified from 100-150 x 106 PBMCs obtained from MiHA-negative individuals
using
MACS cell separation columns (Miltenyi Biotec ) or EasySepTM kits (Stemcell
Technologies ). Monocyte-derived dendritic cells were generated as previously
described (3)
and matured with GM-CSF, IL-4, PGE2, TNFa, IL-16, IL-6 and IFNy. These
dendritic cells were
then irradiated at 40 Gy and pulsed with 2 pg/mL of the synthetic MiHA peptide
(GLRX3-15,
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
WDR27-11-, MIIP-2E, or RASSF1-1s) or an irrelevant peptide (Epstein-Barr virus
LMP2426-434) that
was used a negative control. Pulsed or unpulsed dendritic cells were then co-
cultured with
previously enriched autologous T cells (5x105/well) in 48-well plates in
advanced RPM! medium
supplemented with 10% of human serum, 1% of L-Glutamine and 30 ng/mL of IL-21
at a 1:4
5 (stimulator:effector) ratio. Supplemented media with IL-7 and IL-15 was
added after 3, 5 and 7
days of culture and cells were transferred in 12-well plates and 6-well plates
at day 5 and 7,
respectively. After 10 days of culture, T cells were harvested to determine
antigen reactivity with
ELISpot for IFNy and polyfunctional intracellular cytokine staining. Briefly,
ELISpot analysis was
performed according to the manufacturer's instructions (MABtech ) and
intracellular staining
10 was performed after restimulation with 5 pg/mL of peptide in the
presence of Brefeldin A for 4
hours. Subsequently, cells were stained for CD3 and CD8 surface markers, and
with antibodies
directed against the following cytokines for intracellular staining (obtained
from BD
Biosciences ): IFNy (Ab 4S.B3), IL-2 (Ab MQ1-17H12), TNFa (Ab MAb11), for
intracellular
staining. Acquisition was performed with a BDTM LSR ll flow cytometer and data
were analyzed
15 using FlowlogicTM software (Inivai Technologies ).
Example 2: Identification and characterization of novel human MiHAs
A MiHA is essentially a MAP coded by a genomic region containing an ns-
SNP.13'21 All
human MiHAs discovered to date derive from bi-allelic loci with either two co-
dominant alleles or
20 one dominant and one recessive allele.21'26 Indeed, an ns-SNP in a MAP-
coding sequence will
either hinder MAP generation or generate a variant MAP.11 Hence, at the
peptidomic level, each
allele can be dominant (generate a MAP) or recessive (a null allele that
generates no MAP). All
MiHAs reported in this work were detected by MS and are therefore coded by
dominant alleles.
It was reasoned that two features should dictate which of these MiHAs may
represent adequate
25 targets for immunotherapy of HCs. First, the usefulness of a MiHA is
determined by the allelic
frequency of the MiHA-coding ns-SNP. Indeed, in order to be recognized by
allogeneic T cells,
a MiHA must be present on host cells and absent in donor cells (otherwise,
donor T cells would
not recognize the MiHA as non-self). This situation is referred to as a
"therapeutic mismatch".
The probability to have a therapeutic mismatch is maximal when the allelic
frequency of the
30 target MiHA is 0.5 and decreases as the allele frequency approaches the
two extremes of 0 and
1.14 Thus, MiHA having an allele frequency of 0.01 or 0.99 would yield a low
frequency of
therapeutic mismatch: in the first case, MiHA-positive recipients would be
rare whereas in the
second case, MiHA-negative donors would be difficult to find. As a rule only
variants with a MAF
0.05 are considered as common and balanced genetic polymorphisms.33 Thus, all
MiHAs
35 coded by loci whose least common (minor) allele had a frequency < 0.05
were excluded from
further analyses. Second, the tissue distribution of a MiHA is relevant to
both the efficacy and
the innocuity of MiHA targeting. For HC immunotherapy, the target MiHA must be
expressed in
CA 02974261 2017-07-19
WO 2016/127249
PCT/CA2016/050116
51
hematopoietic cells (including HC cells) but should not be ubiquitously
expressed by host
tissues.
Proteogenomic analyses were performed on B lymphoblastoid cell lines (BLCLs)
from
13 individuals expressing HLA-A*02:01 and/or HLA-B*44:03 allotypes. About 55%
of European
Americans express at least one of these two allotypes. Whole exome and
transcriptome
sequencing was performed for each cell line in order to identify ns-SNPs and
then in silico
translated the genomic sequences to create personalized proteomes. Each
proteome was
subsequently used as a reference to sequence the individual-specific
repertoire of MAPs by
high-throughput MS.26 A total of 6,773 MiHA candidates generated by ns-SNPs
were identified
by MS. However, 96.2% of these ns-SNPs were of limited clinical interest
because they were
rare variants with a MAF < 0.05 (FIG. 1A). Further analyses focused on common
variants, with
a MAF 0.05.33 After filtering and manual MS validation, a total of 100 high-
frequency MiHAs
were identified (Methods, FIG. 2A and Table II), of which 93 were novel (in
white in Table II). In
addition, the MS/MS spectra of the most common MiHAs were confirmed using
synthetic
versions of the peptides.
Table II: Features of MIHAs identified in the studies described herein
Name Sequencel HLA SNP
_ID
ID
ID Ensembl gene ID
_ NO:
ANKRD13A- SLLESSRSQEL/P A0201 rs2287174 ENSG00000076513 79-81
1UP
ANXA2-1V/L ALSGHLETV/L A0201 rs17845226 ENSG00000182718 82-84
APOL1-11/M QELEEKLNI/ML B4403 rs60910145 ENSG00000100342 85-87
ARL2-1V/A REV/ALELDSI B4403 rs664226 ENSG00000213465 88-90
ASCC2-1R/Q R/QLAPTLSQL A0201 rs4823054 ENSG00000100325 91-93
BCS1L-1D/N QEFID/NNPKW B4403 rs58447305 ENSG00000074582 94-96
BLM-1V/I EEIPV/ISSHY B4403 rs7167216 ENSG00000197299 10-12
BLM-2V/I EEIPV/ISSHYF B4403 rs7167216 ENSG00000197299 13-15
BOLA1-1G/A AEELG/AGPVHAL B4403 rs1044808 ENSG00000178096 97-99
CCDC34-1E/A AE/AIQEKKEI B4403 rs17244028 ENSG00000109881 16-18
CCPG1-A/G
SESEDRLVA/G B4403 rs117236526 ENSG00000260916 100-102
CCT3-1UF
ILSEVERNL/F A0201 rs2230194 ENSG00000163468 103-105
CCT3-21N EENGRKEIDI/VKKY B4403 rs11548200 ENSG00000163468 106-108
CENPF-1
NQ/DQ/NH/DH QEN/DIQ/HNLQL B4403 rs3748692 ENSG00000117724 19-23
CENPF-1
NQ/DQ/NH/DH QEN/DIQ/HNLQL B4403 rs3748693 ENSG00000117724 19-23
CEP55-1R/K QEEQTR/KVAL B4403 rs75139274 ENSG00000138180 109-111
COMMD10-11/S I/SLAPCKLETV A0201 rs1129495 ENSG00000145781 112-114
COMMD10-11/S S/ILAPCKLETV A0201 rs1129495 ENSG00000145781 112-114
COPE-1T/I
RSVDVTNT/ITFL A0201 rs10330 ENSG00000105669 115-117
CP0X-1N/H VEEADGN/HKQW B4403 rs1131857 ENSG00000080819 24-26
CP0X-2N/H EEADGN/HKQWW B4403 rs1131857 ENSG00000080819 27-29
DCXR-1A/T
AEVEHVVNA/T B4403 rs61746217 ENSG00000169738 118-120
DNAH8-1A/T
KEIA/TKTVLI B4403 rs1678674 ENSG00000124721 121-123
DYNC2L11-1U1 KUIRGVINQL A0201 rs11556157 ENSG00000138036 124-126
DYNC2L11-1U1 KI/LRGVINQL A0201 rs11556157 ENSG00000138036 124-126
ERAP1-2E/Q
MLRSE/QLLL A0201 rs27044 ENSG00000164307 127-129
GEM I N4-1Q/E RQ/EPDLVLRL A0201
rs2740348 ENSG00000179409 130-132
GM2A-1A/T
LLLAAITPAQA A0201 rs1048719 ENSG00000196743 133-135
HERC3-1E/Q E/QETAIYKGDY B4403 rs1804080 ENSG00000138641 136-138
CA 02974261 2017-07-19
WO 2016/127249
PCT/CA2016/050116
52
HEXB-1IN
LI/VDTSRHYL A0201 rs10805890 ENSG00000049860 139-141
HJURP-1E/G EE/GRGENTSY B4403 rs10511 ENSG00000123485 30-32
HMMR-2R/C KILEKEIR/CV A0201 rs299284 ENSG00000072571 1-3
HMMR-3R/C SESKIR/CVLL B4403 rs299284 ENSG00000072571 33-35
VEVPEAHQL or
HY-KDM5D-1 B4403 Y-linked ENSG00000012817 142
absent
NESNTQKTY or
HY-UTY-2 B4403 Y-linked ENSG00000183878 36
absent2
IKBKAP-11/M MESI/MNPHKY B4403 rs2230794 ENSG00000070061 143-145
KIF20B-11/N
QELETSI/NKKI B4403 rs12572012 ENSG00000138182 146-148
LARS-1N/D
N/DEVLIHSSQY B4403 rs61732383 ENSG00000133706 149-151
MCPH 1-R/I EEINLQR/INI B4403 rs2083914 ENSG00000147316 37-39
MIIP-11QE SEESAVPK/ERSW B4403 rs2295283 ENSG00000116691 40-42
MIIP-1K/E SEESAVPE/KRSW B4403 rs2295283 ENSG00000116691 40-42
MIIP-2K/E EESAVPE/KRSW B4403 rs2295283 ENSG00000116691 43-45
MIIP-2K/E EESAVPK/ERSW B4403 rs2295283 ENSG00000116691 43-45
MIS18BP1-1E/D QE/DLIGKKEY B4403 rs34101857 ENSG00000129534 46-48
MKI67-1G/S EELLAVG/SKF B4403 rs2152143 ENSG00000148773 49-51
MKI67-1G/S EELLAVS/GKF B4403 rs2152143 ENSG00000148773 49-51
MKI67-2D/G G ED/G KG I KAL B4403 rs10082391
ENSG00000148773 52-54
MKNK2-1Q/K AELQ/KGFHRSF B4403 rs3746101 ENSG00000099875 152-154
NDC80-1A/P HLEEQ1A/PKV A0201 rs9051 ENSG00000080986 4-6
NDC80-1A/P HLEEQ1P/AKV A0201 rs9051 ENSG00000080986 4-6
NMRAL1-1T/I T/ILLEDGTFKV A0201 rs11557236 ENSG00000153406 155-157
NMRAL1-1T/I ITTLLEDGTFKV A0201 rs11557236 ENSG00000153406 155-157
N0P56-1 IN VIAEI/VLRGV A0201 rs2273137 ENSG00000101361 158-
160
N0P56-21N
AEI/VLRGVRL B4403 rs2273137 ENSG00000101361 263-265
NUP62-1D/E KLAENID/EAQL A0201 rs892028 ENSG00000213024 161-163
NUP62-2D/E AENID/EAQLKRM B4403 rs892028 ENSG00000213024 164-166
PARP4-1A/T
FLQAKQIAITL A0201 rs2275660 ENSG00000102699 167-169
PARP4-2T/I/R DEIVCT/I/RQHW B4403 rs1372085 ENSG00000102699 170-173
PASK-1F/C
YTWEEVF/CRV A0201 rs1131293 ENSG00000115687 174-176
PFN1-1L/MN KTDKTLVUM/VL A0201 rs13204 ENSG00000108518 177-180
PML-1A/P
SQVQVPLEA/P A0201 rs743582 ENSG00000140464 181-183
P005-1H/R
EEYEELLH/RY B4403 rs2307111 ENSG00000152359 184-186
P005-1H/R
EEYEELLR/HY B4403 rs2307111 ENSG00000152359 184-186
POLR2L-1D/E TEGD/EALDALGLKRY B4403 rs4895
ENSG00000177700 187-189
PPP1CB-1Q/H GQ/HYTDLLRL A0201 rs1128416 ENSG00000213639 190-192
PREX1-1H/Q EEALGLYH/QW B4403 rs41283558 ENSG00000124126 55-57
PRKCD-1E/D
GE/DYFAIKAL B4403 rs2230494 ENSG00000163932 193-195
PRMT1-1E/K IE/KDRQYKDY B4403
rs187325799 ENSG00000126457 196-198
R3HCC1-1H/R AENDFVH/RRI B4403 rs11546682 ENSG00000104679 199-201
RASSF1-1A/S A/SEIEQKIKEY B4403 rs2073498 ENSG00000068028 7-9
RASSF1-1A/S S/AEIEQKIKEY B4403 rs2073498 ENSG00000068028 7-9
RASSF1-2A/S SQA/SEIEQKI A0201 rs2073498 ENSG00000068028 58-60
RN F213-1L/V RL/VLQEQHQL A0201 rs61745599
ENSG00000173821 202-204
RRBP1-1R/L
R/LLQEELEKL A0201 rs1132274 ENSG00000125844 205-207
SCFD2-1L/S
GUSSPLLQKI A0201 rs7675987 ENSG00000184178 208-210
SERF2-1S/P TEMEIS/PRAA B4403 rs12702 ENSG00000242028 61-63
SFI1-1Q/R
EQ/RQLLYRSW B4403 rs2006771 ENSG00000198089 211-213
SMC4-1N/S KEINEKSN/SIL B4403 rs33999879 ENSG00000113810 64-66
TAP1-1D/G
TEVD/GEAGSQL B4403 rs1135216 ENSG00000168394 214-216
TDP2-1Q/E
Q/EEAPESATVIF B4403 rs2294689 ENSG00000111802 217-219
TESPA1-1E/K EE/KEQSQSRW B4403 rs997173 ENSG00000135426 67-69
TMSB10-1E/D TETQE/DKNTL B4403 rs7148 ENSG00000034510 220-222
TPR-1V/I AEV/IRAENL B4403
rs61744267 ENSG00000047410 223-225
TRAPPC5-1S/A AELQS/ARLAA B4403 rs6952 EN5G00000181029 70-72
TRBV6-41/T
LLWAGPVITTA A0201 rs361437 ENSG00000211713 226-228
TRIM22-1N/D KEN/DQEAEKL B4403 rs7935564 EN5G00000132274 229-231
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
53
TRIM5-1Q/R
Q/REYQVKLQA B4403 rs10838525 ENSG00000132256 232-234
TRIM5-1Q/R
R/QEYQVKLQA B4403 rs10838525 ENSG00000132256 232-234
TRMT12-1UMN UMNEADLPRSW B4403 rs11556913 ENSG00000183665 235-238
TROAP-1R/G QENQDPR/GRW B4403 rs8285 ENSG00000135451 73-75
TTI2-1G/E
lEATG/EFDRL B4403 rs2304748 ENSG00000129696 239-241
WDR27-1UP
SUPDDHVVAV A0201 rs4236176 ENSG00000184465 242-244
ZNF417-1H/R QEPFVFH/REF
B4403 rs201944488 ENSG00000060237 245-247
ZWINT-1G/R QELDG/RVFQKL B4403 rs2241666 ENSG00000122952 76-78
ZWINT-1G/R QELDR/GVFQKL B4403 rs2241666 ENSG00000122952 76-78
ACC-2D
KEFEDG/DIINW B4403 rs3826007 ENSG00000140379 248-250
(BCL2A1)
ACC-2G
(BCL2A1)
KEFEDD/GIINW B4403 rs3826007 ENSG00000140379 248-250
BCL2A1-1N/K VLQN/KVAFSV A0201 rs1138358 ENSG00000140379 251-253
GLRX3-1S/P FLS/PSAN EH L A0201 rs2274217
ENSG00000108010 254-256
HMMR-1V/A SLQEKV/AAKA A0201 rs299295 EN5G00000072571 257-259
WNK1-1I/M TLSPEI/M ITV A0201 rs12828016
EN5G00000060237 260-262
1The residues in bold and separated by "/" indicate the amino acid
variation(s) present in the
MiHA.
2The genes from which these MiHAs are derived are located on chromosome Y.
Accordingly, this
MiHa is present in male but absent in female individuals.
3For the MiHAs derived from genes located on chromosome Y, the positions
indicated
correspond to the position of the first residue of the peptide in the protein,
or the position of the
first nucleotide encoding the first residue of the peptide in the transcript.
As a proof of principle, the immunogenicity of four novel MiHAs was tested:
GLRX3-1s,
MIIP-2E, RASSF1-15 and WDR27-11- (FIGs. 3A-3D). T cells from four MiHA-
negative individuals
were primed with autologous dendritic cells pulsed with either a synthetic
MiHA or an irrelevant
peptide. Read-out of antigen-reactivity was assessed by ELISpot (FIG. 3A) and
intracellular
staining assays (FIGs. 3B-3D). Primed T cells produced cytokines in a MiHA-
specific fashion in
all tested donors, confirming that the MiHAs are able to amplify/activate CD8+
T lymphocytes.
Previous MiHA discovery efforts have largely focused on HLA-A*02:01 and to a
lesser
extent on HLA-B*44:03.14,24,34. The proteogenomic approach used herein
increased the total
number of MiHAs presented by HLA-A*02:01 from 21 to 52, and by HLA-B*44:03
from 4 to 67
(FIG. 1B). Although some ns-SNPs generating the 94 novel MiHAs have similar
MAFs in
different populations, the MAF of several ns-SNPs is variable from one
population to another
(FIG. 1C). From a global perspective, these results mean that most of the
MiHAs that were
discovered in individuals of European American origin could also be used to
treat patients from
other populations including Africans and Asians. Previous studies on small
sets of MiHAs have
shown that for most MiHA loci, one (dominant) allele generates a MiHA while
the other
(recessive) allele does not generate a MiHA.21'26 The large MiHA dataset (94
MiHAs coded by
73 genes) confirms and extends this observation: most MiHA-coding ns-SNPs
generated a
single MiHA variant (FIG. 4A). Notably, 18 genes were of particular interest
as they generated
more than one MiHA (FIG. 4B). A logical inference would be that MiHA-coding
genes display a
high degree of genetic polymorphism. In line with this, it was found that MiHA-
coding genes
have a higher ns-SNP density than genes coding invariant HLA class I peptides
(FIG. 4C). Also,
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
54
about 72% of MiHAs arose from a single exon as opposed to exon-exon junctions
(i.e., from two
neighboring exons) (FIG. 4D). This result reflects the intragenic ns-SNP
distribution, since in
MiHA-coding genes the density of ns-SNPs is significantly greater in the
center of exons than in
regions close to junctions (FIG. 4E).
Example 3: MiHAs coded by genes preferentially expressed in hematopoietic
cells
It was assumed that, for HC immunotherapy, optimal MiHAs should be expressed
on
hematopoietic cells, including the target HC cells, but should ideally not be
ubiquitously
expressed. Indeed, ubiquitous expression decreases the efficacy of
immunotherapy by causing
exhaustion of MiHA-specific T cells and entails the risk of toxicity toward
normal host epithelial
cells (Graft-versus-Host-Disease, GvHD). Since the abundance of a MAP shows a
good
correlation with the abundance of its source transcript,22.38-4 and RNA-Seq
is currently the most
accurate method for evaluation of transcript abundance, the expression level
of MiHA-coding
transcripts was evaluated by RNA-Seq. No RNA-Seq data are available for
purified primary
epithelial cells from all anatomic sites, but this information is available
for entire tissues and
organs. Publicly available RNA-Seq data on 27 human tissues from different
individuals30 were
therefore used to assess the expression profile of genes coding the 119 high-
frequency MiHAs
presented by the HLA-A*02:01;B*44:03 haplotype (94 reported herein and 25
previously
reported) (FIG. 5A). The list of previously reported MiHAs is provided in
Table III below.
Table Ill: List of previously reported MiHAs analyzed in the present study
MiHA name Sequence SEQ ID No:
ACC-2G (BCL2A1)* KEFEDD/GI I NW 248
BCL2A1-1N/K* VLQN/KVAFSV 251
C19or148 CIPPDS/TLLFPA 266
FAM119 AMLERQFT/IV 267
GLRX3-1S/P* FLS/PSANEHL 254
HA-1H/R VLH/RDDLLEA 268
HA-2V/M YIGEVLVSV/M 269
HA-8 R/PTLDKVLEV 270
HB-1H EEKRGSLH/YVVV 271
HB-1Y EEKRGSLY/HVW 271
HMMR-1V/A* SLQEKV/AAKA 257
HNF4G MM/IYKD I LLL 272
HY-A2 FIDSYICQV or absent
273
LB-NISCH-1A ALAPAPA/VEV 274
LB-PRCP-1D FMWDVAED/EL 275
LB-PRCP-1D FMWDVAED/ELKA 276
LB-SSR1-1S S/L LAVAQ D LT 277
LB-SSR1-1S VLFRGGPRGS/LLAVA 278
LB-WNK1-1I RTLSPEI/M ITV 279
MY019 RLLEAI I RUF 280
PARP10 GUPLGQEGLVEI 281
SSR1-1L VLFRGGPRGUSLAVA 282
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
T4A GLYTYWSAGA/E 283
UTA2-1 QLL/PNSVLTL 284
WNK1-1I/M* TLSPEI/MITV 260
* detected in the present study (see Table II above)
To evaluate the relative expression of MiHA-coding genes in hematopoietic vs.
epithelial cells, RNA-Seq data obtained from bone marrow vs. skin cells were
used. Skin cells
are not a pure population of epithelial cells (they contain cells of monocytic
and dendritic cell
5 lineage), but are nevertheless highly enriched in epithelial relative to
hematopoietic cells. As a
criterion for preferential expression in hematopoietic cells, an expression
ratio 2 in the bone
marrow relative to the skin was used. Out of 119 MiHAs, 39 (32.8%) were non-
ubiquitous and
overexpressed in hematopoietic cells (FIG. 5A and FIG. 2B).
Acute myeloid leukemia (AML) is the most common indication for AHCT according
to
10 the Center for International Blood and Marrow Transplant Research (CIBMTR,
http://www.cibmtr.org). The expression of genes coding the most promising
MiHAs in AML cells
was thus analyzed using RNA-Seq data from 128 AML samples available from The
Cancer
Genome Atlas (TCGA) (FIG. 56). It was found that the 24 genes coding for the
39 optimal
MiHAs were all expressed in AML. Features of the novel lead MiHAs are shown in
Table IV. The
15 seven (7) other lead MiHAs identified among the 25 previously reported
MiHAs are depicted in
Table V. Hierarchical clustering revealed that MiHA genes could be classified
in 4 major clusters
according to their expression in AMLs (FIG. 5C). This argues for the existence
of interaction or
co-regulation of MiHA genes in discrete clusters.41 Cluster 4 contains MiHA
genes with the
highest expression. Furthermore, nine MiHA genes showed differential
expression among AML
20 subtypes categorized according to the French-American-English
classification42 (FIG. 5C).
Given the correlation between MAP abundance and mRNA expression,
transcriptomic
assessment of MiHA gene expression might be useful for selecting the best MiHA
target for a
given patient.
25 Table IV: Selected features of the novel lead MiHAs described
herein.
SEQ MAF IC50 BM/skin AM Ls
MiHA Name Sequence SNP ID
ID NO: Global/EA (nM) ratio
(RPKM)
HMMR-2mic KILEKEIR/CV 1-3 299284 0.08/0.12 36
3.42 7.31
NDC80-1A/P HLEEQIA/PKV 4-6 9051 0.18/0.23 118/63 4.01
7.47
RASSF1-2A's SQA/SEIEQKI 7-9 2073498 0.08/0.10 2,800 2.39 50.22
BLM-1" EEI PV/ISSHY 10-12 7167216 0.07/0.07 15
9.01 10.50
BLM-2" EEIPV/ISSHYF 13-15 7167216 0.07/0.07 18 9.01 10.50
CCDC34-1 E/A AE/AIQEKKE I 16-18 17244028 0.20/0.35 91
2.14 3.29
CENPF-1 3748692/ 0.10-0.20/
NQ/DCVN1H/DH QEN/DIQ/HNLQL 19-23 518 3.33 10.98
3748693 0.09
CPDX-1" VEEADGN/HKQW 24-26 1131857 0.24/0.13 149 2.06 13.50
CPDX-2" EEADGN/HKQWW 27-29 1131857 0.24/0.13 26 2.06 13.50
HJURP-1E'6 EE/GRGENTSY 30-32 10511 0.18/0.10 220
9.49 7.70
HMMR-3' SESKIFt/CVLL 33-35 299284 0.08/0.12 528 3.42 7.31
HY-UTY-2* NESNTQKTY 36 n.a. 1 (males) 80 4.13
10.78
MCPH1-1 WI EEINLQR/IN I 37-39 2083914 0.08/0.15 104
2.09 6.17
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
56
M I I P-1'vE SE ESAVPK/ERSW 40-42 2295283 0.34/0.29
30/39 2.69 15.57
M I I P-2'vE EESAVPK/ERSW 43-45 2295283 0.34/0.29
45/33 2.69 15.57
MIS18BP1-
1E/D QE/DLIGKKEY 46-48 34101857
0.10/0.08 145 3.58 41.14
MKI67-1 GIS EELLAVG/SKF 49-51 2152143 0.21/0.25 80/39
4.27 20.08
MK167-2w6 GED/GKGIKAL 52-54 10082391 0.22/0.17 3,242 4.27 20.08
PREX1-1m EEALGLYH/QW 55-57 41283558 0.14/0.19 52
8.24 39.64
RASSF1-1A15 S/AE I EQKIKEY 58-60 2073498 0.08/0.10 20/14
2.39 50.22
SERF2-1 5IP TEMEIS/PRAA 61-63 12702 0.21/0.10 235
3.40 61.61
SMC4-1" KEINEKSN/SIL 64-66 33999879 0.05/0.05 861
3.49 42.25
TESPA1-1LIK EE/KEQSQSRW 67-69 997173 0.25/0.07 86 5.49 24.07
TRAPPC5-
1s/A AELQS/ARLAA 70-72 6952 0.34/0.27 472
2.59 30.40
TROAP-1R1 QENQDPR/GRW 73-75 8285 0.05/0.01 21 4.29 8.90
ZW I NT-1('' QELDG/RVFQKL 76-78 2241666 0.26/0.37 210/339
2.61 16.83
In the sequences, the polymorphic residues are underlined and the MiHA
variant(s) detected by
MS is in bold. SNP ID = SNP identifier (SNP ID); MAF Global/EA: Global MAF
reported by
dbSNP, and the MAF in European Americans (EA) reported in the Exome Sequencing
Project
(ESP); IC50 (nm): the predicted HLA binding affinity (IC50) of the detected
MiHA variants
according to NetMHC (v.3.4)58; BM/skin ratio: relative BM/skin expression of
the MiHA-coding
transcripts. AMLs (RPKM): mean MiHA gene expression in primary AML samples
(RPKM)
obtained from TCGA.
Table V: Seven (7) other lead MiHAs identified among the 25 previously
reported MiHAs
SEQ
Peptide Source
MiHA name HLA dbSNP ENSG ID
sequence gene
NO:
ACC-2D
KEFEDGIINW B4403 rs3826007 BCL2A1 ENSG00000140379 248
(BCL2A1 )
ACC-2G
KEFEDDIINW B4403 rs3826007 BCL2A1 ENSG00000140379 248
(BCL2A1 )
BCL2A1-
VLQNVAFSV A0201 rs1138358 BCL2A1 ENSG00000140379 251
1N/K
FAM119 AMLERQFTV A0201 rs2551949 FAM119A ENSG00000144401 267
HA-1H/R VLHDDLLEA A0201 rs1801284 HMHA1 ENSG00000180448 268
73953
HA-2V/M YIGEVLVSV A0201 rs61 MY01G ENSG00000136286 269
1
HMMR-
SLQEKVAKA A0201 rs299295 HMMR ENSG00000072571 257
1V/A
In the cohort of 13 individuals (ten HLA-A*02:01-positive and seven HLA-
B*44:03-
positive) used in the present study, 94 novel high-frequency MiHAs were
identified. It was
calculated that by increasing the number of individuals to 20 for each of
these two allotypes, it
may be expected to increase the total number of high-frequency MiHAs to a
maximum of 125
(FIG. 6A). Such diminishing returns suggest that, from a clinical perspective,
proteogenomic
studies of other common HLA allotypes would be more rewarding. Recent reports
suggest a
dichotomy between generalist and specialist MHC class I allotypes, which
present larger or
smaller MAP repertoires, respectively.43'44 Accordingly, the observation that
HLA-B*44:03
presents more MiHAs (FIG. 6A) suggests that HLA-B*44:03 is a more generalist
allotype, while
HLA-A*02:01 is a more specialist allotype.
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
57
Example 4: Estimating the frequency of therapeutic MiHA mismatches in donor-
recipient
pairs
It was next assessed whether the set of 39 optimal MiHAs defined in the
present study
is sufficient for MiHA-targeted immunotherapy of most patients. One million
transplantation
cases between related or unrelated HLA*02:01/HLA-B*44:03-positive European-
American
donor-recipient pairs were randomly simulated, and the number of therapeutic
MiHA
mismatches found in each case was determined. As shown in FIG. 6B, based on
these
simulations, it was predicted that at least one therapeutic mismatch would be
found in 90% and
98% of related (lower curve) and unrelated (upper curve) donor-recipient
pairs, respectively. In
recent years, the number of unrelated donor transplants has surpassed the
number of related
donor transplants according to the CIBMTR. In the unrelated donor transplant
situation, 2
therapeutic MiHA mismatches would be expected in 92% of cases with a mode of
four
mismatches (FIG. 6C, left bars). It may thus be estimated that the set of 39
optimal MiHAs
would enable MiHA-targeted immunotherapy of practically all HLA-
A*02:01;B*44:03 patients
with HCs.
The scope of the claims should not be limited by the preferred embodiments set
forth in
the examples, but should be given the broadest interpretation consistent with
the description as
a whole.
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
58
REFERENCES
1. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science
2015;348:69-74.
2. Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized
immunotherapy for human
cancer. Science 2015;348:62-68.
3. Sharma P, Allison JP. The future of immune checkpoint therapy. Science
2015;348:56-61.
4. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR et al.
Chimeric antigen
receptor-modified T cells for acute lymphoid leukemia. N.EngLJ Med
2013;368:1509-1518.
5. Maus MV, Fraietta JA, Levine BL, Kalos M, Zhao Y, June CH. Adoptive
immunotherapy for
cancer or viruses. Annu.Revimmunol 2014;32:189-225.
6. Maus MV, Grupp SA, Porter DL, June CH. Antibody modified T cells: CARs take
the front
seat for hematologic malignancies. Blood 2014;123:2625-2635.
7. Reddy P, Maeda Y, Liu C, Krijanovski 01, Korngold R, Ferrara JL. A crucial
role for antigen-
presenting cells and alloantigen expression in graft-versus-leukemia
responses. Nat.Med.
2005;11:1244-1249.
8. Vincent K, Roy DC, Perreault C. Next-generation leukemia immunotherapy.
Blood
2011;118:2951-2959.
9. Mutis T, Brand R, Gallardo D, van BA, Niederwieser D, Goulmy E. Graft-
versus-host driven
graft-versus-leukemia effect of minor histocompatibility antigen HA-1 in
chronic myeloid
leukemia patients. Leukemia 2010;24:1388-1392.
10. Jenq RR, van den Brink MR. Allogeneic haematopoietic stem cell
transplantation:
individualized stem cell and immune therapy of cancer. Nat Rev.Cancer
2010;10:213-221.
11. Roopenian D, Choi EY, Brown A. The immunogenomics of minor
histocompatibility
antigens. ImmunoL Rev. 2002;190:86-94.
12. Mullally A, Ritz J. Beyond HLA: the significance of genomic variation for
allogeneic
hematopoietic stem cell transplantation. Blood 2007;109:1355-1362.
13. Granados DP, Laumont CM, Thibault P, Perreault C. The nature of self for T
cells - a
systems-level perspective. Curr.Opin.ImmunoL 2015;34:1-8.
14. Warren EH, Zhang XC, Li S, Fan W, Storer BE, Chien JW et al. Effect of MHC
and non-
MHC donor/recipient genetic disparity on the outcome of allogeneic HCT. Blood
2012;120:2796-
2806.
15. Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease
biology and
therapy. Nat Rev Immunol 2012;12:443-458.
16. Fontaine P, Roy-Proulx G, Knafo L, Baron C, Roy DC, Perreault C. Adoptive
transfer of T
lymphocytes targeted to a single immunodominant minor histocompatibility
antigen eradicates
leukemia cells without causing graft-versus-host disease. Nat.Med. 2001;7:789-
794.
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
59
17. Meunier MC, Delisle JS, Bergeron J, Rineau V, Baron C, Perreault C. T
cells targeted
against a single minor histocompatibility antigen can cure solid tumors.
Nat.Med. 2005;11:1222-
1229.
18. Li N, Matte-Martone C, Zheng H, Cui W, Venkatesan S, Tan HS et al. Memory
T cells from
minor histocompatibility antigen-vaccinated and virus-immune donors improves
GVL and
immune reconstitution. Blood 2011;118:5965-5976.
19. Blankenstein T, Leisegang M, Uckert W, Schreiber H. Targeting cancer-
specific mutations
by T cell receptor gene therapy. Curr. Opin.Immunol. 2015;33:112-119.
20. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating
immunity's roles in
cancer suppression and promotion. Science 2011;331:1565-1570.
21. Spierings E, Hendriks M, Absi L, Canossi A, Chhaya S, Crowley J et al.
Phenotype
frequencies of autosomal minor histocompatibility antigens display significant
differences among
populations. PLoS.Genet. 2007;3:e103.
22. Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S et al.
Predicting
immunogenic tumour mutations by combining mass spectrometry and exome
sequencing.
Nature 2014;515:572-576.
23. Bleakley M, Riddell SR. Exploiting T cells specific for human minor
histocompatibility
antigens for therapy of leukemia. ImmunaCell Biol. 2011;89:396-407.
24. Hombrink P, Hassan C, Kester MG, Jahn L, Pont MJ, de Ru AH et al.
Identification of
biological relevant minor histocompatibility antigens within the B-lymphocyte-
derived HLA-
ligandome using a reverse immunology approach. Clin.Cancer Res. 2015;21:2177-
2186.
25. Van Bergen CA, Rutten CE, Van Der Meijden ED, Van Luxemburg-Heijs SA,
Lurvink EG,
Houwing-Duistermaat JJ et al. High-throughput characterization of 10 new minor
histocompatibility antigens by whole genome association scanning. Cancer Res.
2010;70:9073-
9083.
26. Granados DP, Sriranganadane D, Daouda T, Zieger A, Laumont CM, Caron-
Lizotte 0 et al.
Impact of genomic polymorphism on the repertoire of human MHC class I-
associated peptides.
Nat Commun 2014;5:3600.
27. Dolan BP, Sharma AA, Gibbs JS, Cunningham TJ, Bennink JR, Yewdell JW. MHC
class I
antigen processing distinguishes endogenous antigens based on their
translation from cellular
vs. viral mRNA. Proc.NatLAcad.ScLU.S.A 2012;109:7025-7030.
28. Yewdell JW. DRiPs solidify: progress in understanding endogenous MHC class
I antigen
processing. Trends ImmunoL 2011;32:548-558.
29. Nesvizhskii Al. Proteogenomics: concepts, applications and computational
strategies. Nat
Methods 2014;11:1114-1125.
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
30. Fagerberg L, Hallstrom BM, Oksvold P, Kampf C, Djureinovic D, Odeberg J et
al. Analysis of
the human tissue-specific expression by genome-wide integration of
transcriptomics and
antibody-based proteomics. Mo/ Cell Proteomics. 2014;13:397-406.
31. Wolf! M, Greenberg PD. Antigen-specific activation and cytokine-
facilitated expansion of
5 naive, human CD8+ T cells. Nat Protoc. 2014;9:950-966.
32. JaneIle V, Carli C, Taillefer J, Orio J, Delisle JS. Defining novel
parameters for the optimal
priming and expansion of minor histocompatibility antigen-specific T cells in
culture. J
Transl.Med. 2015;13:123.
33. Abecasis GR, Altshuler D, Auton A, Brooks LD, Durbin RM, Gibbs RA et al. A
map of human
10 genome variation from population-scale sequencing. Nature 2010;467:1061-
1073.
34. Spierings E. Minor histocompatibility antigens: past, present, and future.
Tissue Antigens
2014;84:374-60.
35. Majewski J, Ott J. Distribution and characterization of regulatory
elements in the human
genome. Genome Res. 2002;12:1827-1836.
15 36. Asakura S, Hashimoto D, Takashima S, Sugiyama H, Maeda Y, Akashi K
et al. Alloantigen
expression on non-hematopoietic cells reduces graft-versus-leukemia effects in
mice.
J.Clin.Invest 2010;120:2370-2378.
37. Flutter B, Edwards N, Fallah-Arani F, Henderson S, Chai JG, Sivakumaran S
et al.
Nonhematopoietic antigen blocks memory programming of alloreactive CD8+ T
cells and drives
20 their eventual exhaustion in mouse models of bone marrow
transplantation. J.Clininvest
2010;120:3855-3868.
38. Fortier MH, Caron E, Hardy MP, Voisin G, Lemieux S, Perreault C et al. The
MHC class I
peptide repertoire is molded by the transcriptome. J.Exp.Med. 2008;205:595-
610.
39. Hoof I, van Baarle D, Hildebrand WH, Kesmir C. Proteome sampling by the
HLA class I
25 antigen processing pathway. PLoS.ComputBiol. 2012;8:e1002517.
40. Granados DP, Yahyaoui W, Laumont CM, Daouda T, Muratore-Schroeder TL, Cote
C et al.
MHC I-associated peptides preferentially derive from transcripts bearing miRNA
response
elements. Blood 2012;119:e181-e191.
41. Caron E, Vincent K, Fortier MH, Laverdure JP, Bramoulle A, Hardy MP et al.
The MHC I
30 immunopeptidome conveys to the cell surface an integrative view of
cellular regulation.
Mol.Syst.Biol. 20117:533.
42. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et
al. Proposed
revised criteria for the classification of acute myeloid leukemia. A report of
the French-
American-British Cooperative Group. Ann.Intem.Med. 1985;103:620-625.
35 43. Chappell P, Meziane EK, Harrison M, Magiera L, Hermann C, Mears L et
al. Expression
levels of MHC class I molecules are inversely correlated with promiscuity of
peptide binding.
Elife. 2015;4:e05345.
CA 02974261 2017-07-19
WO 2016/127249 PCT/CA2016/050116
61
44. Schellens IM, Hoof I, Meiring HD, Spijkers SN, Poelen MC, van Gaans-van
den Brink JA et
al. Comprehensive analysis of the naturally processed peptide repertoire:
differences between
HLA-A and B in the immunopeptidome. PLoS.One. 2015;10:e0136417.
45. Caron E, Espona L, Kowalewski DJ, Schuster H, Ternette N, Alpizar A et al.
An open-source
computational and data resource to analyze digital maps of immunopeptidomes.
Elife. 2015;4:
46. Heath WR, Carbone FR. The skin-resident and migratory immune system in
steady state
and memory: innate lymphocytes, dendritic cells and T cells. Nat Immunol
2013;14:978-985.
47. Bollard CM, Barrett AJ. Cytotoxic T lymphocytes for leukemia and lymphoma.
Hematology.Am.Soc.HematoLEduc.Program. 2014;2014:565-569.
48. Yee C. The use of endogenous T cells for adoptive transfer. Immunol Rev
2014;257:250-
263.
49. Perreault C, Roy DC, Fortin C. Immunodominant minor histocompatibility
antigens: the
major ones. ImmunoL Today 1998;19:69-74.
50. Choi EY, Christianson GJ, Yoshimura Y, Jung N, Sproule TJ, Malarkannan S
et al. Real-
time T-cell profiling identifies H60 as a major minor histocompatibility
antigen in murine graft-
versus-host disease. Blood 2002;100:4259-4264.
51. Kim J, Ryu SJ, Oh K, Ju JM, Jeon JY, Nam G et al. Memory programming in
CD8(+) T-cell
differentiation is intrinsic and is not determined by CD4 help. Nat Commun
2015;6:7994.
52. Rosinski SL, Stone B, Graves SS, Fuller DH, De Rosa SC, Spies GA et al.
Development of
a minor histocompatibility antigen vaccine regimen in the canine model of
hematopoietic cell
transplantation. Transplantation 2015;99:2083-2094.
53. Turtle CJ, Riddell SR. Genetically retargeting CD8+ lymphocyte subsets for
cancer
immunotherapy. Curr.Opin.ImmunoL 2011;23:299-305.
54. Nauerth M, Weissbrich B, Knall R, Franz T, Dossinger G, Bet J et al. TCR-
ligand koff rate
correlates with the protective capacity of antigen-specific CD8+ T cells for
adoptive transfer.
ScLTransl.Med. 2013;5:192ra87.
55. Ghosh A, Holland AM, van den Brink MR. Genetically engineered donor T
cells to optimize
graft-versus-tumor effects across MHC barriers. Immunol Rev 2014;257:226-236.
56. June CH, Riddell SR, Schumacher TN. Adoptive cellular therapy: A race to
the finish line.
ScLTransLMed. 2015;7:280ps7.
57. Torikai H, Reik A, Soldner F, Warren EH, Yuen C, Zhou Y et al. Toward
eliminating HLA
class I expression to generate universal cells from allogeneic donors. Blood
2013;122:1341-
1349.
58. Inaguma Y, Akahori Y, Murayama Y, Shiraishi K, Tsuzuki-lba S, Endoh A et
al. Construction
and molecular characterization of a T-cell receptor-like antibody and CAR-T
cells specific for
minor histocompatibility antigen HA-1H. Gene Ther. 2014;21:575-584.
